

**Prevalence and age patterns of depression in the United Kingdom. A population-based study.**

**Running title: Prevalence and age patterns of depression in the United Kingdom.**

Jorge Arias de la Torre<sup>1,2</sup>, Gemma Vilagut<sup>2,3</sup>, Amy Ronaldson<sup>1</sup>, Alex Dregan<sup>1</sup>, Ignacio Ricci-Cabello<sup>2</sup>, Stephani L Hatch<sup>1,4</sup>, Antoni Serrano-Blanco<sup>2,5</sup>, Jose M Valderas<sup>6</sup>, Matthew Hotopf<sup>1,7</sup>, Jordi Alonso<sup>2,3,8</sup>.

<sup>1</sup> Institute of Psychiatry, Psychology and Neurosciences (IoPPN), King's College London, London, UK.

<sup>2</sup> CIBER Epidemiology and Public Health (CIBERESP), Madrid, Spain

<sup>3</sup> Health Services Research Group, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain

<sup>4</sup> ESRC Centre for Society and Mental Health, King's College London, London, UK.

<sup>5</sup> Institut de Recerca Sant Joan de Déu, Parc Sanitari Sant Joan de Déu, Barcelona, Spain.

<sup>6</sup> Health Services and Policy Research Group, University of Exeter, Exeter, UK.

<sup>7</sup> South London and Maudsley NHS Foundation Trust, London, United Kingdom.

<sup>8</sup> Dept. of Experimental and Health Sciences, Pompeu Fabra University (UPF), Barcelona, Spain

**Short Report**

**Word count: 2,873**

**Corresponding author:**

**Jorge Arias de la Torre**

Department of Psychological Medicine, Division of Academic Psychiatry

Institute of Psychiatry, Psychology and Neuroscience (IoPPN)

King's College London, De Crespigny Park, London SE5 8AF

+44 754309727 [Jorge.arias\\_de\\_la\\_torre@kcl.ac.uk](mailto:Jorge.arias_de_la_torre@kcl.ac.uk)

1 **Abstract (248 words)**

2 **Background:** Identifying variations by age in the prevalence of depression would be  
3 instrumental in supporting case detection and targeted prevention. Our aim was to determine  
4 these variations in the UK. **Methods:** A representative sample of the UK population (n=17,152)  
5 from the European Health Interview Survey of 2014 was included in the analyses. The Patient  
6 Health Questionnaire (PHQ-8) was used to assess the prevalence of depressive symptoms and  
7 of probable depressive disorder. Prevalence estimates (95%CI) were calculated. The  
8 association between prevalence and age was assessed using multivariable multinomial logistic  
9 and logistic regression models. All analyses were carried out for the total sample and stratified  
10 by sex. **Results:** The prevalence of depressive symptoms ranged from 11.3% (10.6-11.9) for  
11 mild, to 3.3% (3.0-3.7) for severe symptoms. The prevalence of probable depressive disorder  
12 was 7.5% (95%CI: 7.0-8.0). A significantly higher prevalence of probable depressive disorder  
13 was found in those aged 45 to 59 years old compared with those aged 16 to 29. For the  
14 prevalence of severe depressive symptoms those age differences were even higher: 2.55 times  
15 higher (5.38 for men and 1.75 for women). **Limitations:** The cross-sectional design precludes  
16 establishing the direction of the relationship between age and the prevalence. **Conclusions:** The  
17 prevalence and age patterns of depression in the UK were described. A peak in the prevalence  
18 was identified during middle adulthood. These results could serve as a reference for the  
19 monitoring of depression in the UK and the development of preventive strategies, particularly  
20 in the high-risk population groups identified.

21

22

23 **Keywords:** *Depression; PHQ-8; Prevalence; Age; Survey studies.*

24

25

## 26 **Introduction**

27 Depressive disorders are prevalent and place a significant burden on patients and health  
28 systems (James et al., 2018; World Health Organization, 2017). These disorders are one of the  
29 foremost causes of disability, are associated with reductions in quality of life for patients and  
30 their families, and generate a substantial expenditure of resources for health systems (James et  
31 al., 2018; Kyu et al., 2018; Moussavi et al., 2007). Variations by country and over time in the  
32 prevalence of depression have been systematically reported (Auerbach et al., 2016;  
33 Bretschneider et al., 2018; Bromet et al., 2011; James et al., 2018; World Health Organisation  
34 (WHO), 2011). A periodic evaluation for each country could be highly valuable for monitoring  
35 the prevalence of depression, planning health resources and to improve preventive measures  
36 through identifying higher risk groups.

37 In the United Kingdom (UK), the Adult Psychiatric Morbidity Survey (APMS) has provided  
38 information on Mental Health and Wellbeing in the population aged 16 and over since 1993  
39 (NHS Digital, 2014). Whilst the emphasis of APMS is on common mental disorders, including  
40 both depression and anxiety, it also reports the prevalence of depressive episode assessed using  
41 the Clinical Interview Schedule-Revised (CIS-R) (Lewis et al., 1992). This prevalence was  
42 estimated by the APMS in 2014 to be between 2% and 6%. However, since 2007 the APMS  
43 collects information only for England and not for Scotland, Wales and Northern Ireland. In  
44 addition to the APMS, other studies within the UK have tried to determine the prevalence of  
45 depression such as the Outcome of Depression International Network study (ODIN) or the  
46 South East London Community Health Study (SELCoH) (Ayuso-Mateos et al., 2001; Hatch et  
47 al., 2012). These studies, based in selected samples from Liverpool in the case of the ODIN  
48 study (Ayuso-Mateos et al., 2001), and south east London in the case of the SELCoH study  
49 (Hatch et al., 2012), have reported higher prevalence estimates for depression, varying between  
50 5% and 15% depending on the specific study. Besides the differences in the population

51 considered, variations in the figures reported could be caused by different factors, such as  
52 differences in the study period and in the measure of depression severity (Chang et al., 2008).  
53 Hence, to obtain a clear representation of the prevalence and severity of depressive symptoms  
54 in the UK, it would be appropriate to make an assessment using a population representative  
55 sample of the whole country.

56 Both sex and age have been systematically related to the prevalence of depression (Arias-de la  
57 Torre et al., 2018; Kessler et al., 2010; Patel et al., 2018a). While a higher prevalence of  
58 depressive symptoms has consistently been found in women compared to men, the relationship  
59 of the prevalence with age is less clear. The most recent APMS suggested a peak of prevalence  
60 among the middle-aged population, independent of their sex, and a possible increased  
61 prevalence of depressive symptoms in young women (NHS Digital, 2014). It should also be  
62 highlighted that the relationship between age and the prevalence of depressive symptoms might  
63 vary depending on depression severity (Salk et al., 2017). While the younger population might  
64 have higher rates of mild depression, the prevalence of severe depression could be higher  
65 among the older population (Patel et al., 2018b).

66 Taking this into consideration, the aims of the current study were: a) to determine the  
67 prevalence of depressive symptoms and of probable depressive disorder in the UK, and b) to  
68 examine its association with age and sex.

## 69 **Methods**

70 A cross-sectional study using data from the UK edition of the second wave of the European  
71 Health Interview Survey (EHIS) was carried out. EHIS is a nationwide representative survey  
72 conducted in all EU member states, Iceland, Norway and Turkey, which began in 2006  
73 (Eurostat, 2018). A survey was conducted for the second wave between 2013 and 2015  
74 including health related and socioeconomic variables (Eurostat, 2015). The EHIS sample for

75 the UK was selected using a simple random sampling method based on the household as the  
76 sampling unit. This sampling method, in essence, consists of random selection from the target  
77 population of the number of households required to reach a previously determined effective  
78 sample size, after assigning weights to the selected households according to their  
79 characteristics. Approximately 25% of the sample was interviewed face-to-face and 75% by  
80 telephone, with a response rate about 60%. The non-response rate was compensated in EHIS  
81 using an approach based on sample sizes and weighting. The minimum effective sample size  
82 is the size required if the survey was based on simple random sampling. The actual sample size  
83 is the number of sample units interviewed. The actual sample size should be larger to the extent  
84 that the design effects exceed 1.0 and to compensate for all kinds of non-response (Eurostat,  
85 2018). In the UK, the ratio between the actual effective sample size and the estimated minimum  
86 effective sample size was 1.08 and thus it could be assumed that the effects of the non-response  
87 rate were compensated. In addition, EHIS sampling weights were designed to compensate  
88 unequal probabilities of selection and non-response adjustments (Eurostat, 2018). For this  
89 study, we included 17,706 non-institutionalized individuals that completed the 8-item Patient  
90 Health Questionnaire (PHQ-8), a valid and reliable tool used to assess depressive symptoms  
91 based on DSM-IV criteria(Wu et al., 2019). Individuals with missing values in any of the  
92 independent variables were excluded (n=554; 3.1%).

### 93 *Study measures*

94 The presence of depressive symptoms and of probable depressive disorder assessed with the  
95 PHQ-8 were the main outcomes of the study. PHQ-8 questionnaire is composed of 8 Likert  
96 type items with responses ranging from 0 (Not at all) to 3 (Nearly every day). The final score  
97 is computed by adding the score for each of the items ranging from 0 to 24. In accordance with  
98 the developmental study of the PHQ-8 (Kroenke et al., 2009), to assess depressive symptoms,  
99 a categorical variable with the following levels was considered: mild (PHQ-8: 5-9), moderate

100 (PHQ-8: 10-14) and severe depressive symptoms (PHQ-8 $\geq$ 15). Additionally, to assess  
101 probable depressive disorder, a score equal to or higher than 10 (PHQ-8 $\geq$ 10) was considered  
102 as positive. According to previous validation studies (Levis et al., 2019; Wu et al., 2019), this  
103 cut-off value has a sensitivity  $>75\%$  and a specificity  $>85\%$  to detect depressive disorders  
104 including major depressive disorder and dysthymia.

105 The main explanatory factor of this study was age (categorical: 16 to 29, 30 to 44, 45 to 59, 60  
106 to 74 and 75 or more years old). Furthermore, based on evidence from previous research (Arias-  
107 de la Torre et al., 2018; De Wit et al., 2009; Maske et al., 2016; Onyike et al., 2003; Rai et al.,  
108 2013), sex and the following confounders were considered as covariates for the adjustment of  
109 models: interview method, birthplace, degree of urbanization of the individuals' residence area,  
110 Body Mass Index (BMI) derived from self-reported height and weight of participants  
111 (categorized), and social support evaluated with the Oslo Social Support (OSS) scale and  
112 considered as a categorical variable (Kocalevent et al., 2018).

### 113 *Statistical analysis*

114 A descriptive analysis of the characteristics of the study sample was carried out. The prevalence  
115 of depressive symptoms, of probable depressive disorder and their 95% Confidence Intervals  
116 (95%CI) according to age and sex were calculated. To assess the relationship of the prevalence  
117 with age, bivariable and multivariable multinomial (polytomous) logistic regression models for  
118 depressive symptoms and binary logistic regression models for probable depressive disorder  
119 (PHQ-8 $\geq$ 10) were performed. From these models, crude and adjusted Relative Odds Ratios  
120 (ROR and aROR respectively) and crude and adjusted Odds Ratios (OR and aOR respectively)  
121 together with their 95%CI were obtained (Szklo and Nieto, 2014). To assess the statistical  
122 significance of age within the models, Wald tests were used. Multivariable regression models  
123 were adjusted by all the covariates selected. The absence of multicollinearity and of interaction

124 between all the covariates and age were tested. To ensure representativeness and to obtain  
125 variance estimates that account for the sampling design, sampling weights using Taylor series  
126 linearization were applied for the analyses(West and McCabe, 2012). The level of significance  
127 was set at 0.01. All analyses were performed using the statistical software Stata v.16 (“Stata  
128 Statistical Software: Release 16,” 2019).

## 129 **Results**

130 Analyses were carried out in a sample of 17,152 individuals, of whom. 53.8% were women,  
131 88.1% were born in the UK (88.1% of men and 88.2% of women), 54.4% resided in densely  
132 populated areas (53.4% of men and 55.2% of women), 45.1% had a BMI between 18.5 and  
133 24.9 (40.9% of men and 48.7% of women) and had moderate-strong social support according  
134 to the OSS score (Table1).

135 The prevalence of both depressive symptoms and of a probable depressive disorder was higher  
136 among women than among men. Table 2 shows the distribution of the prevalence of depressive  
137 symptoms and probable depressive disorder by age and sex. The prevalence of depressive  
138 symptoms ranged from 11.3% (95%CI 10.6-11.9) for mild depressive symptoms, 4.2%  
139 (95%CI: 3.8-4.6) for moderate depressive symptoms and 3.3% (95%CI: 3.0-3.7) for severe  
140 depressive symptoms (Supplementary file 1). The prevalence of a probable depressive disorder  
141 was 7.5% (95%CI: 7.0-8.0). A higher prevalence of probable depressive disorder was observed  
142 for those aged 45 to 59 for both sex (Figure 1). Among men, lower prevalence was found in  
143 the younger population (16 to 29 years old) both in all levels of depressive symptoms and in  
144 probable depressive disorder. Among women, a higher prevalence was found in younger (16  
145 to 29), middle-aged (45 to 59) and older (75 or more) population groups both in all levels of  
146 depressive symptoms except for mild, and in probable depressive disorder.

147 Significant differences related to age were only found in severe depressive symptoms (Table  
148 3). A higher prevalence of severe symptoms was found among those between 45 to 59 years  
149 old compared with those aged 16 to 29 years (aROR: 2.55 95%CI: 1.60-4.06). For men,  
150 statistically significant differences in the prevalence of mild and severe depressive symptoms  
151 related to age were found. The prevalence of mild depressive symptoms (aROR: 1.76, 95%CI:  
152 1.15-2.71) and severe depressive symptoms (aROR: 5.38, 95%CI: 2.51-11.53) was higher in  
153 middle-age men (45-59 years) than in younger men (16-29 years). Among women,  
154 significantly higher prevalence of severe symptoms (ROR: 1.78, 95%CI: 1.04-3.06) was found  
155 at the bivariable level in the middle-aged (45-59 years) group compared with younger (16-29  
156 years) women. In multivariable analysis, the prevalence of severe depressive symptoms was  
157 higher in middle-aged women compared to younger women (aROR: 1.75, 95%CI: 0.99-3.10),  
158 but this difference was not statistically significant.

159 The prevalence of probable depressive disorder (PHQ-8 $\geq$ 10) was also related with age (Table  
160 4). The group aged between 45 and 59 years had a significantly higher prevalence than the  
161 younger population in the total sample (aOR: 1.82, 95%CI: 1.32-2.50) and in men (aOR: 2.84,  
162 95%CI: 1.57-5.14). Among women, while statistically significant differences were found for  
163 the group aged between 45 and 59 at bivariable level (OR: 1.48, 95%CI: 1.03-2.12), no  
164 significant differences at multivariable level were found.

## 165 **Discussion**

166 Based on a representative sample, our study showed that the prevalence of depressive  
167 symptoms in the UK ranged from 11.3% with mild symptoms to 3.3% with severe depressive  
168 symptoms. Furthermore, the prevalence of probable depressive disorder in the UK was 7.5%  
169 (6.2% and 8.6% for men and women respectively). All these estimates varied largely according



170 to age with a peak of prevalence, particularly of severe depressive symptoms, in the population  
171 aged between 45 to 59 years old.

172 The prevalence estimates of probable depressive disorder reported in the present study are  
173 slightly higher than those reported by the APMS in 2014 using a different measure (CIS-R)  
174 (NHS Digital, 2014), but are similar to those observed in the same year in other high-income  
175 countries using the PHQ-8 such as Germany (around 7.4%) and Spain (approximately 6.5%)  
176 (Arias-de la Torre et al., 2018; Bretschneider et al., 2018). Regarding the higher prevalence we  
177 found compared to the APMS, it is important to note that the measures used to ascertain  
178 depression (PHQ-8 in the former and CIS-R in the latter) are different. It should be mentioned  
179 the possible differences related to the timeframe of the tools used for the evaluation of  
180 depression (two weeks for the PHQ-8 used in EHIS and one week for the CIS-R used in the  
181 APMS). The use of a screening tool to determine probable depressive disorder, as is the PHQ-  
182 8, could lead to classify as cases some individuals that, while at risk of having a depressive  
183 disorder, might not be classified as such using a structured interview as CIS-R. In addition, the  
184 study populations also varied between EHIS and the APMS: EHIS examined a representative  
185 sample from the whole UK, whereas the APMS focused on England only. Despite these  
186 differences, variation in the prevalence patterns by age were similar in both surveys, with a  
187 clear peak between age 45 and 59 for both sex (NHS Digital, 2014). Accordingly, our results  
188 corroborate that individuals between 45 and 59 years are the age group with the highest risk of  
189 depression in the UK.

190 It should be noted that a higher crude prevalence was found in women than men in all age  
191 groups and a significantly higher prevalence was found in most of the cases only for the group  
192 between 45 to 59 years old. Among men aged 45 to 59 years, the prevalence of probable  
193 depressive disorder was almost triple that found in the youngest group, and this increased to  
194 more than 5.3 times higher for severe symptoms. In women, the prevalence of severe

195 depressive symptoms was more than 1.7 times higher than in younger women. It should be  
196 highlighted that while among men the relationship of age with the prevalence of depressive  
197 symptoms becomes more relevant as severity increases, among women the strength of these  
198 relationships is lower. These results suggest that the role of age as a determinant of depression  
199 might vary according to both sex and the severity level considered. Moreover, these findings  
200 might be explained by a number of reasons, such as period factors (e.g. the possible higher  
201 impact on group aged 45 to 59 of the previous economic recession period, particularly in those  
202 belonging to the most disadvantaged groups) and other potential mediators in the relationship  
203 of age and depression (e.g. inflammation increasing with age or family and social roles) (Arias-  
204 de la Torre et al., 2019b, 2019a; Dijkstra-Kersten et al., 2015; Dregan et al., 2020; Hong et al.,  
205 2011; Niedzwiedz et al., 2017; Perry et al., 2020). Further longitudinal research to elucidate  
206 the causes of the increased rates of depression in this age group in the UK could be valuable to  
207 better understand them. Furthermore, the results suggest that targeted screening and preventive  
208 strategies in this high-risk population group (middle-aged adults) may help reduce the  
209 prevalence of depression in the UK population, particularly in the case of severe depression.

210 Evidence from other countries (Arias-de la Torre et al., 2018; Luppá et al., 2012; Maske et al.,  
211 2016), suggests that the prevalence of depression tends to increase as the age increases. Such  
212 variability between countries in the age patterns, might be explained by methodological and  
213 health-related factors, such as differences in the populations analyzed and reporting bias  
214 between countries, differences in the access to health care resources and treatments in older  
215 population, and differences in welfare regimes and social protection policies. Due to the high  
216 differences between countries in these factors, the prevalence in the middle-age group might  
217 be higher in the UK than in southern or central European countries (Arias-de la Torre et al.,  
218 2019b; Bambra, 2011; Bambra and Eikemo, 2008; Reibling, 2010). New research using  
219 homogeneous samples from countries with different healthcare systems and social protection

220 policies, could be valuable to understand differences between countries in the age patterns of  
221 depression.

222 Another finding was the high prevalence of mild depressive symptoms found in those aged 75  
223 years or more (9.3% for men and 12.9% for women) and in younger women (14.4%). The mild  
224 depressive symptoms category is under the cut-off value (10+) consistently proposed to  
225 determine the presence of depression using the PHQ-8 and, therefore, could be indicative of  
226 subclinical depression or depressive mood (Levis et al., 2019; Moriarty et al., 2015; Salk et al.,  
227 2017). In older ages, the presence of mild depressive symptoms are strongly associated with  
228 an increased risk of mortality, decline of overall health status and low quality of life (Cai et al.,  
229 2020; Holwerda et al., 2016; Sivertsen et al., 2015). In younger women, while in many cases  
230 mild depressive symptoms could have a remission in the late 20s (Patton et al., 2014), some of  
231 them could develop more severe symptoms and a depressive disorder over adulthood. These  
232 results suggest that the mild symptomatic group in early adulthood might be a fruitful target  
233 for early intervention or targeted preventive strategies.

234 Some limitations of the study should be discussed. First, the use of a screening tool to determine  
235 the presence of probable depressive disorder and the severity of depressive symptoms.  
236 However, the PHQ-8 shows suitable psychometric properties for its use as a screening tool  
237 when compared to clinical interviews, showing a very high (but not perfect) sensitivity and  
238 specificity to detect major depressive disorders at the general population level (Levis et al.,  
239 2019; Moriarty et al., 2015; Wu et al., 2019). Another limitation is related to potential bias  
240 from how the information on depressive symptoms was gathered (approximately 25% of the  
241 sample was interviewed face-to-face and 75% by telephone). However, previous evidence  
242 suggests that the information gathering methods might not influence the results when assessing  
243 psychiatric disorders (Fenig et al., 1993; Rohde et al., 1997), and particularly when using the  
244 PHQ (Pinto-Meza et al., 2005). Additionally, despite the differences in the prevalence in the

245 sample used in our study (Supplementary file 2) and their potential influence in the  
246 relationships shown, as the interview method was adjusted for in multivariable, this potential  
247 source of bias could be considered, at least, partially controlled. Future research considering  
248 the potential effect of different administration methods could be valuable to obtain new  
249 evidence related to this aspect and improve the accuracy of mental health interview surveys. It  
250 should be also mentioned that people with mental disorders could be less likely to participate  
251 in cross-sectional population surveys and therefore our results may be under-estimates of true  
252 population prevalence (Arias-de la Torre et al., 2020; Knudsen et al., 2010). Despite this  
253 limitation, as our aim was to assess differences in prevalence according to age, the relationships  
254 and patterns found might be considered relevant although under-estimation is possible. It  
255 should be also noted the lack of inclusion of socioeconomic status and other sociodemographic  
256 variables (e.g. educational level and marital status) in multivariable models. These variables  
257 could interact with age having a mediational or indirect effect in the relationship between age  
258 and depression. Therefore, including these interactions within the multivariable models, could  
259 lead to misinterpretations of the differences in prevalence by age. Finally, we should point out  
260 that EHIS data has no information on other relevant variables, such as ethnicity or family  
261 history of depression. However, EHIS captures a wide range of variables consistently related  
262 to the prevalence of depressive symptoms (e.g. age, sex, demographic factors, BMI, and social  
263 support) (Eurostat, 2018). Therefore, the results of the current study could be considered as  
264 relevant in terms of their capability to be extrapolated to the UK population.

265 In conclusion, our study shows the prevalence of depressive symptoms (from 11.3% with mild  
266 symptoms to 3.3% with severe symptoms) and of probable depressive disorder (7.5%) in the  
267 UK. Furthermore, a clear peak in the prevalence of depression, and particularly of severe  
268 depressive symptoms, was identified during middle adulthood (from 45 to 59 years). Given the  
269 representativeness of the sample (including England, Scotland, Wales, and Northern Ireland)

270 these results could serve as a reference for the monitoring of depression in the UK, the planning  
271 of health resources, and the development of preventive and screening strategies targeting the  
272 higher risk population groups identified.

## 273 **References**

274 Arias-de la Torre, J., Fernández-Villa, T., Molina, A., Amezcua-Prieto, C., Mateos, R.,  
275 Cancela, J., Delgado-Rodríguez, M., Ortíz-Moncada, R., Alguacil, J., Redondo, S.,  
276 Gómez-Acebo, I., Morales-Suárez-Varela, M., Blázquez Abellán, G., Jiménez Mejías,  
277 E., Valero, L., Ayán, C., Vilorio-Marqués, L., Olmedo-Requena, R., Martín, V., 2019a.  
278 Psychological Distress, Family Support and Employment Status in First-Year University  
279 Students in Spain. *Int. J. Environ. Res. Public Health* 16, 1209.

280 <https://doi.org/10.3390/ijerph16071209>

281 Arias-de la Torre, J., Molina, A.J., Fernández-Villa, T., Artazcoz, L., Martín, V., 2019b.  
282 Mental health, family roles and employment status inside and outside the household in  
283 Spain. *Gac. Sanit.* 33, 235–241. <https://doi.org/10.1016/j.gaceta.2017.11.005>

284 Arias-de la Torre, J., Valderas, J.M., Benavides, F.G., Alonso, J., 2020. Cardboard floor:  
285 about the barriers for social progression and their impact on the representativeness of  
286 epidemiological studies. *J. Epidemiol. Community Health* jech-2020-214978.

287 <https://doi.org/10.1136/jech-2020-214978>

288 Arias-de la Torre, J., Vilagut, G., Martín, V., Molina, A.J., Alonso, J., 2018. Prevalence of  
289 major depressive disorder and association with personal and socio-economic factors.

290 Results for Spain of the European Health Interview Survey 2014–2015. *J. Affect.*  
291 *Disord.* 239, 203–207. <https://doi.org/10.1016/j.jad.2018.06.051>

292 Auerbach, R.P., Alonso, J., Axinn, W.G., Cuijpers, P., Ebert, D.D., Green, J.G., Hwang, I.,  
293 Kessler, R.C., Liu, H., Mortier, P., Nock, M.K., Pinder-Amaker, S., Sampson, N.A.,

294 Aguilar-Gaxiola, S., Al-Hamzawi, A., Andrade, L.H., Benjet, C., Caldas-de-Almeida,  
295 J.M., Demyttenaere, K., Florescu, S., de Girolamo, G., Gureje, O., Haro, J.M., Karam,  
296 E.G., Kiejna, A., Kovess-Masfety, V., Lee, S., McGrath, J.J., O’Neill, S., Pennell, B.-E.,  
297 Scott, K., Ten Have, M., Torres, Y., Zaslavsky, A.M., Zarkov, Z., Bruffaerts, R., 2016.  
298 Mental disorders among college students in the World Health Organization World  
299 Mental Health Surveys. *Psychol. Med.* 46, 2955–2970.  
300 <https://doi.org/10.1017/S0033291716001665>

301 Ayuso-Mateos, J.L., Vázquez-Barquero, J.L., Dowrick, C., Lehtinen, V., Dalgard, O.S.,  
302 Casey, P., Wilkinson, C., Lasa, L., Page, H., Dunn, G., Wilkinson, G., Ballesteros, J.,  
303 Birkbeck, G., Børve, T., Costello, M., Cuijpers, P., Davies, I., Diez-Manrique, J.F.,  
304 Fenlon, N., Finne, M., Ford, F., Gaité, L., Gomez del Barrio, A., Hayes, C., Herrán, A.,  
305 Horgan, A., Koffert, T., Jones, N., Lehtilä, M., McDonough, C., Michalak, E., Murphy,  
306 C., Nevra, A., Nummelin, T., Sohlman, B., 2001. Depressive disorders in Europe:  
307 Prevalence figures from the ODIN study. *Br. J. Psychiatry.*  
308 <https://doi.org/10.1192/bjp.179.4.308>

309 Bamba, C., 2011. Health inequalities and welfare state regimes: Theoretical insights on a  
310 public health “puzzle.” *J. Epidemiol. Community Health.*  
311 <https://doi.org/10.1136/jech.2011.136333>

312 Bamba, C., Eikemo, T.A., 2008. Welfare state regimes, unemployment and health: a  
313 comparative study of the relationship between unemployment and self-reported health in  
314 23 European countries. *J. Epidemiol. Community Heal.* 63, 92–98.  
315 <https://doi.org/10.1136/jech.2008.077354>

316 Bretschneider, J., Janitza, S., Jacobi, F., Thom, J., Hapke, U., Kurth, T., Maske, U.E., 2018.  
317 Time trends in depression prevalence and health-related correlates: results from

318 population-based surveys in Germany 1997–1999 vs. 2009–2012. *BMC Psychiatry* 18,  
319 394. <https://doi.org/10.1186/s12888-018-1973-7>

320 Bromet, E., Andrade, L.H., Hwang, I., Sampson, N.A., Alonso, J., de Girolamo, G., de Graaf,  
321 R., Demyttenaere, K., Hu, C., Iwata, N., Karam, A.N., Kaur, J., Kostyuchenko, S.,  
322 Lépine, J.-P., Levinson, D., Matschinger, H., Mora, M.E.M., Browne, M.O., Posada-  
323 Villa, J., Viana, M.C., Williams, D.R., Kessler, R.C., 2011. Cross-national epidemiology  
324 of DSM-IV major depressive episode. *BMC Med.* 9, 90. [https://doi.org/10.1186/1741-](https://doi.org/10.1186/1741-7015-9-90)  
325 [7015-9-90](https://doi.org/10.1186/1741-7015-9-90)

326 Cai, W., Mueller, C., Shetty, H., Perera, G., Stewart, R., 2020. Predictors of mortality in  
327 people with late-life depression: A retrospective cohort study. *J. Affect. Disord.* 266,  
328 695–701. <https://doi.org/10.1016/j.jad.2020.01.021>

329 Chang, S.M., Hahm, B.J., Lee, J.Y., Shin, M.S., Jeon, H.J., Hong, J.P., Lee, H.B., Lee, D.W.,  
330 Cho, M.J., 2008. Cross-national difference in the prevalence of depression caused by the  
331 diagnostic threshold. *J. Affect. Disord.* <https://doi.org/10.1016/j.jad.2007.07.023>

332 De Wit, L.M., Van Straten, A., Van Herten, M., Penninx, B.W., Cuijpers, P., 2009.  
333 Depression and body mass index, a u-shaped association. *BMC Public Health.*  
334 <https://doi.org/10.1186/1471-2458-9-14>

335 Dijkstra-Kersten, S.M.A., Biesheuvel-Leliefeld, K.E.M., van der Wouden, J.C., Penninx,  
336 B.W.J.H., van Marwijk, H.W.J., 2015. Associations of financial strain and income with  
337 depressive and anxiety disorders. *J. Epidemiol. Community Health* 69, 660–5.  
338 <https://doi.org/10.1136/jech-2014-205088>

339 Dregan, A., Rayner, L., Davis, K.A.S., Bakolis, I., Arias De La Torre, J., Das-Munshi, J.,  
340 Hatch, S.L., Stewart, R., Hotopf, M., 2020. Associations between Depression, Arterial  
341 Stiffness, and Metabolic Syndrome among Adults in the UK Biobank Population Study:

342 A Mediation Analysis. *JAMA Psychiatry*.  
343 <https://doi.org/10.1001/jamapsychiatry.2019.4712>

344 Eurostat, 2018. Quality report of the second wave of the European Health Interview survey.  
345 Eurostat, 2015. European Health Interview Survey second wave (EHIS).

346 Fenig, S., Levav, I., Kohn, R., Yelin, N., 1993. Telephone vs face-to-face interviewing in a  
347 community psychiatric survey. *Am. J. Public Health*.  
348 <https://doi.org/10.2105/AJPH.83.6.896>

349 Hatch, S.L., Woodhead, C., Frissa, S., Fear, N.T., Verdecchia, M., Stewart, R., Reichenberg,  
350 A., Morgan, C., Bebbington, P., McManus, S., Brugha, T., Kankulu, B., Clark, J.L.,  
351 Gazard, B., Medcalf, R., Hotopf, M., 2012. Importance of Thinking Locally for Mental  
352 Health: Data from Cross-Sectional Surveys Representing South East London and  
353 England. *PLoS One* 7, e48012. <https://doi.org/10.1371/journal.pone.0048012>

354 Holwerda, T.J., Van Tilburg, T.G., Deeg, D.J.H., Schutter, N., Dekker, J., Stek, M.L.,  
355 Beekman, A.T.F., Schoevers, R.A., Rien, V., 2016. Impact of loneliness and depression  
356 on mortality: Results from the longitudinal ageing study Amsterdam. *Br. J. Psychiatry*.  
357 <https://doi.org/10.1192/bjp.bp.115.168005>

358 Hong, J., Knapp, M., Mcguire, A., 2011. Income-related inequalities in the prevalence of  
359 depression and suicidal behaviour: A 10-year trend following economic crisis. *World*  
360 *Psychiatry*. <https://doi.org/10.1002/j.2051-5545.2011.tb00012.x>

361 James, S.L., Abate, D., Abate, K.H., Abay, S.M., Abbafati, C., Abbasi, N., Abbastabar, H.,  
362 Abd-Allah, F., Abdela, J., Abdelalim, A., Abdollahpour, I., Abdulkader, R.S., Abebe, Z.,  
363 Abera, S.F., Abil, O.Z., Abraha, H.N., Abu-Raddad, L.J., Abu-Rmeileh, N.M.E.,  
364 Accrombessi, M.M.K., Acharya, D., Acharya, P., Ackerman, I.N., Adamu, A.A.,



365 Adebayo, O.M., Adekanmbi, V., Adetokunboh, O.O., Adib, M.G., Adsuar, J.C., Afanvi,  
366 K.A., Afarideh, M., Afshin, A., Agarwal, G., Agesa, K.M., Aggarwal, R., Aghayan,  
367 S.A., Agrawal, S., Ahmadi, A., Ahmadi, M., Ahmadi, H., Ahmed, M.B., Aichour,  
368 A.N., Aichour, I., Aichour, M.T.E., Akinyemiju, T., Akseer, N., Al-Aly, Z., Al-Eyadhy,  
369 A., Al-Mekhlafi, H.M., Al-Raddadi, R.M., Alahdab, F., Alam, K., Alam, T., Alashi, A.,  
370 Alavian, S.M., Alene, K.A., Alijanzadeh, M., Alizadeh-Navaei, R., Aljunid, S.M.,  
371 Alkerwi, A., Alla, F., Allebeck, P., Alouani, M.M.L., Altirkawi, K., Alvis-Guzman, N.,  
372 Amare, A.T., Aminde, L.N., Ammar, W., Amoako, Y.A., Anber, N.H., Andrei, C.L.,  
373 Androudi, S., Animut, M.D., Anjomshoa, M., Ansha, M.G., Antonio, C.A.T., Anwari,  
374 P., Arabloo, J., Arauz, A., Aremu, O., Ariani, F., Armoon, B., Ärnlov, J., Arora, A.,  
375 Artaman, A., Aryal, K.K., Asayesh, H., Asghar, R.J., Ataro, Z., Atre, S.R., Ausloos, M.,  
376 Avila-Burgos, L., Avokpaho, E.F.G.A., Awasthi, A., Ayala Quintanilla, B.P., Ayer, R.,  
377 Azzopardi, P.S., Babazadeh, A., Badali, H., Badawi, A., Bali, A.G., Ballesteros, K.E.,  
378 Ballew, S.H., Banach, M., Banoub, J.A.M., Banstola, A., Barac, A., Barboza, M.A.,  
379 Barker-Collo, S.L., Bärnighausen, T.W., Barrero, L.H., Baune, B.T., Bazargan-Hejazi,  
380 S., Bedi, N., Beghi, E., Behzadifar, Masoud, Behzadifar, Meysam, Béjot, Y., Belachew,  
381 A.B., Belay, Y.A., Bell, M.L., Bello, A.K., Bensenor, I.M., Bernabe, E., Bernstein, R.S.,  
382 Beuran, M., Beyranvand, T., Bhala, N., Bhattarai, S., Bhaumik, S., Bhutta, Z.A., Biadgo,  
383 B., Bijani, A., Bikbov, B., Bilano, V., Bililign, N., Bin Sayeed, M.S., Bisanzio, D.,  
384 Blacker, B.F., Blyth, F.M., Bou-Orm, I.R., Boufous, S., Bourne, R., Brady, O.J.,  
385 Brainin, M., Brant, L.C., Brazinova, A., Breitborde, N.J.K., Brenner, H., Briant, P.S.,  
386 Briggs, A.M., Briko, A.N., Britton, G., Brugha, T., Buchbinder, R., Busse, R., Butt,  
387 Z.A., Cahuana-Hurtado, L., Cano, J., Cárdenas, R., Carrero, J.J., Carter, A., Carvalho,  
388 F., Castañeda-Orjuela, C.A., Castillo Rivas, J., Castro, F., Catalá-López, F., Cercy,  
389 K.M., Cerin, E., Chaiah, Y., Chang, A.R., Chang, H.-Y., Chang, J.-C., Charlson, F.J.,

390 Chattopadhyay, A., Chattu, V.K., Chaturvedi, P., Chiang, P.P.-C., Chin, K.L., Chitheer,  
391 A., Choi, J.-Y.J., Chowdhury, R., Christensen, H., Christopher, D.J., Cicuttini, F.M.,  
392 Ciobanu, L.G., Cirillo, M., Claro, R.M., Collado-Mateo, D., Cooper, C., Coresh, J.,  
393 Cortesi, P.A., Cortinovis, M., Costa, M., Cousin, E., Criqui, M.H., Cromwell, E.A.,  
394 Cross, M., Crump, J.A., Dadi, A.F., Dandona, L., Dandona, R., Dargan, P.I., Daryani,  
395 A., Das Gupta, Rajat, Das Neves, J., Dasa, T.T., Davey, G., Davis, A.C., Davitioiu, D.V.,  
396 De Courten, B., De La Hoz, F.P., De Leo, D., De Neve, J.-W., Degefa, M.G.,  
397 Degenhardt, L., Deiparine, S., Dellavalle, R.P., Demoz, G.T., Deribe, K., Dervenis, N.,  
398 Des Jarlais, D.C., Dessie, G.A., Dey, S., Dharmaratne, S.D., Dinberu, M.T., Dirac,  
399 M.A., Djalalinia, S., Doan, L., Dokova, K., Doku, D.T., Dorsey, E.R., Doyle, K.E.,  
400 Driscoll, T.R., Dubey, M., Dubljanin, E., Duken, E.E., Duncan, B.B., Duraes, A.R.,  
401 Ebrahimi, H., Ebrahimpour, S., Echko, M.M., Edvardsson, D., Effiong, A., Ehrlich, J.R.,  
402 El Bcheraoui, C., El Sayed Zaki, M., El-Khatib, Z., Elkout, H., Elyazar, I.R.F., Enayati,  
403 A., Endries, A.Y., Er, B., Erskine, H.E., Eshrati, B., Eskandarieh, S., Esteghamati, A.,  
404 Esteghamati, S., Fakhim, H., Fallah Omrani, V., Faramarzi, M., Fareed, M., Farhadi, F.,  
405 Farid, T.A., Farinha, C.S.E. sá, Farioli, A., Faro, A., Farvid, M.S., Farzadfar, F., Feigin,  
406 V.L., Fentahun, N., Fereshtehnejad, S.-M., Fernandes, E., Fernandes, J.C., Ferrari, A.J.,  
407 Feyissa, G.T., Filip, I., Fischer, F., Fitzmaurice, C., Foigt, N.A., Foreman, K.J., Fox, J.,  
408 Frank, T.D., Fukumoto, T., Fullman, N., Fürst, T., Furtado, J.M., Futran, N.D., Gall, S.,  
409 Ganji, M., Gankpe, F.G., Garcia-Basteiro, A.L., Gardner, W.M., Gebre, A.K.,  
410 Gebremedhin, A.T., Gebremichael, T.G., Gelano, T.F., Geleijnse, J.M., Genova-  
411 Maleras, R., Geramo, Y.C.D., Gething, P.W., Gezae, K.E., Ghadiri, K., Ghasemi  
412 Falavarjani, K., Ghasemi-Kasman, M., Ghimire, M., Ghosh, R., Ghoshal, A.G.,  
413 Giampaoli, S., Gill, P.S., Gill, T.K., Ginawi, I.A., Giussani, G., Gnedovskaya, E. V,  
414 Goldberg, E.M., Goli, S., Gómez-Dantés, H., Gona, P.N., Gopalani, S.V., Gorman,

415 T.M., Goulart, A.C., Goulart, B.N.G., Grada, A., Grams, M.E., Grosso, G., Gugnani,  
416 H.C., Guo, Y., Gupta, P.C., Gupta, Rahul, Gupta, Rajeev, Gupta, T., Gyawali, B.,  
417 Haagsma, J.A., Hachinski, V., Hafezi-Nejad, N., Haghparast Bidgoli, H., Hagos, T.B.,  
418 Hailu, G.B., Haj-Mirzaian, Arvin, Haj-Mirzaian, Arya, Hamadeh, R.R., Hamidi, S.,  
419 Handal, A.J., Hankey, G.J., Hao, Y., Harb, H.L., Harikrishnan, S., Haro, J.M., Hasan,  
420 M., Hassankhani, H., Hassen, H.Y., Havmoeller, R., Hawley, C.N., Hay, R.J., Hay, S.I.,  
421 Hedayatizadeh-Omran, A., Heibati, B., Hendrie, D., Henok, A., Herteliu, C.,  
422 Heydarpour, S., Hibstu, D.T., Hoang, H.T., Hoek, H.W., Hoffman, H.J., Hole, M.K.,  
423 Homaie Rad, E., Hoogar, P., Hosgood, H.D., Hosseini, S.M., Hosseinzadeh, M.,  
424 Hostiuc, M., Hostiuc, S., Hotez, P.J., Hoy, D.G., Hsairi, M., Htet, A.S., Hu, G., Huang,  
425 J.J., Huynh, C.K., Iburg, K.M., Ikeda, C.T., Ileanu, B., Ilesanmi, O.S., Iqbal, U., Irvani,  
426 S.S.N., Irvine, C.M.S., Islam, S.M.S., Islami, F., Jacobsen, K.H., Jahangiry, L.,  
427 Jahanmehr, N., Jain, S.K., Jakovljevic, M., Javanbakht, M., Jayatilleke, A.U., Jeemon,  
428 P., Jha, R.P., Jha, V., Ji, J.S., Johnson, C.O., Jonas, J.B., Jozwiak, J.J., Jungari, S.B.,  
429 Jürisson, M., Kabir, Z., Kadel, R., Kahsay, A., Kalani, R., Kanchan, T., Karami, M.,  
430 Karami Matin, B., Karch, A., Karema, C., Karimi, N., Karimi, S.M., Kasaeian, A.,  
431 Kassa, D.H., Kassa, G.M., Kassa, T.D., Kassebaum, N.J., Katikireddi, S.V., Kawakami,  
432 N., Karyani, A.K., Keighobadi, M.M., Keiyoro, P.N., Kemmer, L., Kemp, G.R.,  
433 Kengne, A.P., Keren, A., Khader, Y.S., Khafaei, B., Khafaie, M.A., Khajavi, A., Khalil,  
434 I.A., Khan, E.A., Khan, M.S., Khan, M.A., Khang, Y.-H., Khazaei, M., Khoja, A.T.,  
435 Khosravi, A., Khosravi, M.H., Kiadaliri, A.A., Kiirithio, D.N., Kim, C.-I., Kim, D.,  
436 Kim, P., Kim, Y.-E., Kim, Y.J., Kimokoti, R.W., Kinfu, Y., Kisa, A., Kissimova-  
437 Skarbek, K., Kivimäki, M., Knudsen, A.K.S., Kocarnik, J.M., Kochhar, S., Kokubo, Y.,  
438 Kolola, T., Kopec, J.A., Kosen, S., Kotsakis, G.A., Koul, P.A., Koyanagi, A.,  
439 Kravchenko, M.A., Krishan, K., Krohn, K.J., Kuate Defo, B., Kucuk Bicer, B., Kumar,

440 G.A., Kumar, M., Kyu, H.H., Lad, D.P., Lad, S.D., Lafranconi, A., Laloo, R., Lallukka,  
441 T., Lami, F.H., Lansingh, V.C., Latifi, A., Lau, K.M.-M., Lazarus, J. V, Leasher, J.L.,  
442 Ledesma, J.R., Lee, P.H., Leigh, J., Leung, J., Levi, M., Lewycka, S., Li, S., Li, Y.,  
443 Liao, Y., Liben, M.L., Lim, L.-L., Lim, S.S., Liu, S., Lodha, R., Looker, K.J., Lopez,  
444 A.D., Lorkowski, S., Lotufo, P.A., Low, N., Lozano, R., Lucas, T.C.D., Lucchesi, L.R.,  
445 Lunevicius, R., Lyons, R.A., Ma, S., Macarayan, E.R.K., Mackay, M.T., Madotto, F.,  
446 Magdy Abd El Razek, H., Magdy Abd El Razek, M., Maghavani, D.P., Mahotra, N.B.,  
447 Mai, H.T., Majdan, M., Majdzadeh, R., Majeed, A., Malekzadeh, R., Malta, D.C.,  
448 Mamun, A.A., Manda, A.-L., Manguerra, H., Manhertz, T., Mansournia, M.A.,  
449 Mantovani, L.G., Mapoma, C.C., Maravilla, J.C., Marcenes, W., Marks, A., Martins-  
450 Melo, F.R., Martopullo, I., März, W., Marzan, M.B., Mashamba-Thompson, T.P.,  
451 Massenburg, B.B., Mathur, M.R., Matsushita, K., Maulik, P.K., Mazidi, M., McAlinden,  
452 C., McGrath, J.J., McKee, M., Mehndiratta, M.M., Mehrotra, R., Mehta, K.M., Mehta,  
453 V., Mejia-Rodriguez, F., Mekonen, T., Melese, A., Melku, M., Meltzer, M., Memiah,  
454 P.T.N., Memish, Z.A., Mendoza, W., Mengistu, D.T., Mengistu, G., Mensah, G.A.,  
455 Mereta, S.T., Meretoja, A., Meretoja, T.J., Mestrovic, T., Mezerji, N.M.G., Miazgowski,  
456 B., Miazgowski, T., Milllear, A.I., Miller, T.R., Miltz, B., Mini, G.K., Mirarefin, M.,  
457 Mirrakhimov, E.M., Misganaw, A.T., Mitchell, P.B., Mitiku, H., Moazen, B., Mohajer,  
458 B., Mohammad, K.A., Mohammadifard, N., Mohammadnia-Afrouzi, M., Mohammed,  
459 M.A., Mohammed, S., Mohebi, F., Moitra, M., Mokdad, A.H., Molokhia, M., Monasta,  
460 L., Moodley, Y., Moosazadeh, M., Moradi, G., Moradi-Lakeh, M., Moradinazar, M.,  
461 Moraga, P., Morawska, L., Moreno Velásquez, I., Morgado-Da-Costa, J., Morrison,  
462 S.D., Moschos, M.M., Mountjoy-Venning, W.C., Mousavi, S.M., Mruts, K.B., Muche,  
463 A.A., Muchie, K.F., Mueller, U.O., Muhammed, O.S., Mukhopadhyay, S., Muller, K.,  
464 Mumford, J.E., Murhekar, M., Musa, J., Musa, K.I., Mustafa, G., Nabhan, A.F., Nagata,

465 C., Naghavi, M., Naheed, A., Nahvijou, A., Naik, G., Naik, N., Najafi, F., Naldi, L.,  
466 Nam, H.S., Nangia, V., Nansseu, J.R., Nascimento, B.R., Natarajan, G., Neamati, N.,  
467 Negoi, I., Negoi, R.I., Neupane, S., Newton, C.R.J., Ngunjiri, J.W., Nguyen, A.Q.,  
468 Nguyen, Ha Thu, Nguyen, H.L.T., Nguyen, Huong Thanh, Nguyen, L.H., Nguyen, M.,  
469 Nguyen, N.B., Nguyen, S.H., Nichols, E., Ningrum, D.N.A., Nixon, M.R., Nolutshungu,  
470 N., Nomura, S., Norheim, O.F., Noroozi, M., Norrving, B., Noubiap, J.J., Nouri, H.R.,  
471 Nourollahpour Shiadeh, M., Nowroozi, M.R., Nsoesie, E.O., Nyasulu, P.S., Odell, C.M.,  
472 Ofori-Asenso, R., Ogbo, F.A., Oh, I.-H., Oladimeji, O., Olagunju, A.T., Olagunju, T.O.,  
473 Olivares, P.R., Olsen, H.E., Olusanya, B.O., Ong, K.L., Ong, S.K., Oren, E., Ortiz, A.,  
474 Ota, E., Otstavnov, S.S., Øverland, S., Owolabi, M.O., P A, M., Pacella, R., Pakpour,  
475 A.H., Pana, A., Panda-Jonas, S., Parisi, A., Park, E.-K., Parry, C.D.H., Patel, S., Pati, S.,  
476 Patil, S.T., Patle, A., Patton, G.C., Paturi, V.R., Paulson, K.R., Pearce, N., Pereira, D.M.,  
477 Perico, N., Pesudovs, K., Pham, H.Q., Phillips, M.R., Pigott, D.M., Pillay, J.D., Piradov,  
478 M.A., Pirsheh, M., Pishgar, F., Plana-Ripoll, O., Plass, D., Polinder, S., Popova, S.,  
479 Postma, M.J., Pourshams, A., Poustchi, H., Prabhakaran, D., Prakash, S., Prakash, V.,  
480 Purcell, C.A., Purwar, M.B., Qorbani, M., Quistberg, D.A., Radfar, A., Rafay, A.,  
481 Rafiei, A., Rahim, F., Rahimi, K., Rahimi-Movaghar, A., Rahimi-Movaghar, V.,  
482 Rahman, M., Rahman, M.H. ur, Rahman, M.A., Rahman, S.U., Rai, R.K., Rajati, F.,  
483 Ram, U., Ranjan, P., Ranta, A., Rao, P.C., Rawaf, D.L., Rawaf, S., Reddy, K.S., Reiner,  
484 R.C., Reinig, N., Reitsma, M.B., Remuzzi, G., Renzaho, A.M.N., Resnikoff, S., Rezaei,  
485 S., Rezai, M.S., Ribeiro, A.L.P., Roberts, N.L.S., Robinson, S.R., Roever, L., Ronfani,  
486 L., Roshandel, G., Rostami, A., Roth, G.A., Roy, A., Rubagotti, E., Sachdev, P.S.,  
487 Sadat, N., Saddik, B., Sadeghi, E., Saeedi Moghaddam, S., Safari, H., Safari, Y., Safari-  
488 Faramani, R., Safdarian, M., Safi, S., Safiri, S., Sagar, R., Sahebkar, A., Sahraian, M.A.,  
489 Sajadi, H.S., Salam, N., Salama, J.S., Salamati, P., Saleem, K., Saleem, Z., Salimi, Y.,

490 Salomon, J.A., Salvi, S.S., Salz, I., Samy, A.M., Sanabria, J., Sang, Y., Santomauro,  
491 D.F., Santos, I.S., Santos, J.V., Santric Milicevic, M.M., Sao Jose, B.P., Sardana, M.,  
492 Sarker, A.R., Sarrafzadegan, N., Sartorius, B., Sarvi, S., Sathian, B., Satpathy, M.,  
493 Sawant, A.R., Sawhney, M., Saxena, S., Saylan, M., Schaeffner, E., Schmidt, M.I.,  
494 Schneider, I.J.C., Schöttker, B., Schwebel, D.C., Schwendicke, F., Scott, J.G., Sekerija,  
495 M., Sepanlou, S.G., Serván-Mori, E., Seyedmousavi, S., Shabaninejad, H., Shafieesabet,  
496 A., Shahbazi, M., Shaheen, A.A., Shaikh, M.A., Shams-Beyranvand, M., Shamsi, M.,  
497 Shamsizadeh, M., Sharafi, H., Sharafi, K., Sharif, M., Sharif-Alhoseini, M., Sharma, M.,  
498 Sharma, R., She, J., Sheikh, A., Shi, P., Shibuya, K., Shigematsu, M., Shiri, R.,  
499 Shirkoohi, R., Shishani, K., Shiue, I., Shokraneh, F., Shoman, H., Shrimel, M.G., Si, S.,  
500 Siabani, S., Siddiqi, T.J., Sigfusdottir, I.D., Sigurvinsdottir, R., Silva, J.P., Silveira,  
501 D.G.A., Singam, N.S.V., Singh, J.A., Singh, N.P., Singh, V., Sinha, D.N., Skiadaresi, E.,  
502 Slepak, E.L.N., Sliwa, K., Smith, D.L., Smith, M., Soares Filho, A.M., Sobaih, B.H.,  
503 Sobhani, S., Sobngwi, E., Soneji, S.S., Soofi, M., Soosaraei, M., Sorensen, R.J.D.,  
504 Soriano, J.B., Soyiri, I.N., Sposato, L.A., Sreeramareddy, C.T., Srinivasan, V.,  
505 Stanaway, J.D., Stein, D.J., Steiner, C., Steiner, T.J., Stokes, M.A., Stovner, L.J., Subart,  
506 M.L., Sudaryanto, A., Sufiyan, M.B., Sunguya, B.F., Sur, P.J., Sutradhar, I., Sykes,  
507 B.L., Sylte, D.O., Tabarés-Seisdedos, R., Tadakamadla, S.K., Tadesse, B.T., Tandon,  
508 N., Tassew, S.G., Tavakkoli, M., Taveira, N., Taylor, H.R., Tehrani-Banihashemi, A.,  
509 Tekalign, T.G., Tekelemedhin, S.W., Tekle, M.G., Temesgen, H., Temsah, M.-H.,  
510 Temsah, O., Terkawi, A.S., Teweldemedhin, M., Thankappan, K.R., Thomas, N.,  
511 Tilahun, B., To, Q.G., Tonelli, M., Topor-Madry, R., Topouzis, F., Torre, A.E.,  
512 Tortajada-Girbés, M., Touvier, M., Tovani-Palone, M.R., Towbin, J.A., Tran, B.X.,  
513 Tran, K.B., Troeger, C.E., Truelsen, T.C., Tsilimbaris, M.K., Tsoi, D., Tudor Car, L.,  
514 Tuzcu, E.M., Ukwaja, K.N., Ullah, I., Undurraga, E.A., Unutzer, J., Updike, R.L.,

515 Usman, M.S., Uthman, O.A., Vaduganathan, M., Vaezi, A., Valdez, P.R., Varughese, S.,  
516 Vasankari, T.J., Venketasubramanian, N., Villafaina, S., Violante, F.S., Vladimirov,  
517 S.K., Vlassov, V., Vollset, S.E., Vosoughi, K., Vujcic, I.S., Wagnew, F.S., Waheed, Y.,  
518 Waller, S.G., Wang, Y., Wang, Y.-P., Weiderpass, E., Weintraub, R.G., Weiss, D.J.,  
519 Weldegebreal, F., Weldegwergs, K.G., Werdecker, A., West, T.E., Whiteford, H.A.,  
520 Widecka, J., Wijeratne, T., Wilner, L.B., Wilson, S., Winkler, A.S., Wiyeh, A.B.,  
521 Wiysonge, C.S., Wolfe, C.D.A., Woolf, A.D., Wu, S., Wu, Y.-C., Wyper, G.M.A.,  
522 Xavier, D., Xu, G., Yadgir, S., Yadollahpour, A., Yahyazadeh Jabbari, S.H., Yamada,  
523 T., Yan, L.L., Yano, Y., Yaseri, M., Yasin, Y.J., Yeshaneh, A., Yimer, E.M., Yip, P.,  
524 Yisma, E., Yonemoto, N., Yoon, S.-J., Yotebieng, M., Younis, M.Z., Yousefifard, M.,  
525 Yu, C., Zadnik, V., Zaidi, Z., Zaman, S. Bin, Zamani, M., Zare, Z., Zeleke, A.J., Zenebe,  
526 Z.M., Zhang, K., Zhao, Z., Zhou, M., Zodpey, S., Zucker, I., Vos, T., Murray, C.J.L.,  
527 2018. Global, regional, and national incidence, prevalence, and years lived with  
528 disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a  
529 systematic analysis for the Global Burden of Disease Study 2017. *Lancet* 392, 1789–  
530 1858. [https://doi.org/10.1016/S0140-6736\(18\)32279-7](https://doi.org/10.1016/S0140-6736(18)32279-7)

531 Kessler, R.C., Birnbaum, H., Bromet, E., Hwang, I., Sampson, N., Shahly, V., 2010. Age  
532 differences in major depression: Results from the national comorbidity survey  
533 replication (NCS-R). *Psychol. Med.* <https://doi.org/10.1017/S0033291709990213>

534 Knudsen, A.K., Hotopf, M., Skogen, J.C., Øverland, S., Mykletun, A., 2010. The health  
535 status of nonparticipants in a population-based health study. *Am. J. Epidemiol.*  
536 <https://doi.org/10.1093/aje/kwq257>

537 Kocalevent, R.D., Berg, L., Beutel, M.E., Hinz, A., Zenger, M., Härter, M., Nater, U.,  
538 Brähler, E., 2018. Social support in the general population: Standardization of the Oslo

539 social support scale (OSSS-3). *BMC Psychol.* [https://doi.org/10.1186/s40359-018-0249-](https://doi.org/10.1186/s40359-018-0249-9)  
540 9

541 Kroenke, K., Strine, T.W., Spitzer, R.L., Williams, J.B.W., Berry, J.T., Mokdad, A.H., 2009.  
542 The PHQ-8 as a measure of current depression in the general population. *J. Affect.*  
543 *Disord.* 114, 163–173. <https://doi.org/10.1016/j.jad.2008.06.026>

544 Kyu, H.H., Abate, D., Abate, K.H., Abay, S.M., Abbafati, C., Abbasi, N., Abbastabar, H.,  
545 Abd-Allah, F., Abdela, J., Abdelalim, A., Abdollahpour, I., Abdulkader, R.S., Abebe,  
546 M., Abebe, Z., Abil, O.Z., Aboyans, V., Abrham, A.R., Abu-Raddad, L.J., Abu-  
547 Rmeileh, N.M.E., Accrombessi, M.M.K., Acharya, D., Acharya, P., Ackerman, I.N.,  
548 Adamu, A.A., Adebayo, O.M., Adekanmbi, V., Ademi, Z., Adetokunboh, O.O., Adib,  
549 M.G., Adsuar, J.C., Afanvi, K.A., Afarideh, M., Afshin, A., Agarwal, G., Agesa, K.M.,  
550 Aggarwal, R., Aghayan, S.A., Agrawal, A., Ahmadi, A., Ahmadi, M., Ahmadieh, H.,  
551 Ahmed, M.B., Ahmed, S., Aichour, A.N., Aichour, I., Aichour, M.T.E., Akinyemiju, T.,  
552 Akseer, N., Al-Aly, Z., Al-Eyadhy, A., Al-Mekhlafi, H.M., Al-Raddadi, R.M., Alahdab,  
553 F., Alam, K., Alam, T., Alashi, A., Alavian, S.M., Alene, K.A., Alijanzadeh, M.,  
554 Alizadeh-Navaei, R., Aljunid, S.M., Alkerwi, A., Alla, F., Allebeck, P., Alonso, J.,  
555 Alsharif, U., Altirkawi, K., Alvis-Guzman, N., Aminde, L.N., Amini, E., Amiresmaili,  
556 M., Ammar, W., Amoako, Y.A., Anber, N.H., Andrei, C.L., Androudi, S., Animut,  
557 M.D., Anjomshoa, M., Ansha, M.G., Antonio, C.A.T., Anwari, P., Arabloo, J., Aremu,  
558 O., Ärnlöv, J., Arora, A., Arora, M., Artaman, A., Aryal, K.K., Asayesh, H., Ataro, Z.,  
559 Ausloos, M., Avila-Burgos, L., Avokpaho, E.F.G.A., Awasthi, A., Ayala Quintanilla,  
560 B.P., Ayer, R., Azzopardi, P.S., Babazadeh, A., Badali, H., Balakrishnan, K., Bali, A.G.,  
561 Banach, M., Banoub, J.A.M., Barac, A., Barboza, M.A., Barker-Collo, S.L.,  
562 Bärnighausen, T.W., Barquera, S., Barrero, L.H., Bazargan-Hejazi, S., Bedi, N., Beghi,  
563 E., Behzadifar, Masoud, Behzadifar, Meysam, Bekele, B.B., Bekru, E.T., Belachew,



564 A.B., Belay, Y.A., Bell, M.L., Bello, A.K., Bennett, D.A., Bensenor, I.M., Berhane, A.,  
565 Bernabe, E., Bernstein, R.S., Beuran, M., Beyranvand, T., Bhala, N., Bhatt, S.,  
566 Bhaumik, S., Bhutta, Z.A., Biadgo, B., Biehl, M.H., Bijani, A., Bikbov, B., Bilano, V.,  
567 Bililign, N., Bin Sayeed, M.S., Bisanzio, D., Bjorge, T., Bleyer, A., Bobasa, E.M., Bou-  
568 Orm, I.R., Boufous, S., Bourne, R., Brady, O.J., Brant, L.C., Brayne, C., Brazinova, A.,  
569 Breitborde, N.J.K., Brenner, H., Briant, P.S., Briko, A.N., Britton, G., Brugha, T.,  
570 Buchbinder, R., Busse, R., Butt, Z.A., Cahuana-Hurtado, L., Campuzano Rincon, J.C.,  
571 Cano, J., Cárdenas, R., Carrero, J.J., Carter, A., Carvalho, F., Castaneda-Orjuela, C.A.,  
572 Rivas, J.C., Castro, F., Catalá-López, F., Cercy, K.M., Cerin, E., Chaiah, Y., Chang,  
573 J.C., Charlson, F.J., Chattu, V.K., Chiang, P.P.C., Chitheer, A., Choi, J.Y.J.,  
574 Christensen, H., Christopher, D.J., Chung, S.C., Cicuttini, F.M., Cirillo, M., Collado-  
575 Mateo, D., Cooper, C., Cortesi, P.A., Cortinovia, M., Cousin, E., Criqui, M.H.,  
576 Cromwell, E.A., Cross, M., Crump, J.A., Daba, A.K., Dachew, B.A., Dadi, A.F.,  
577 Dandona, L., Dandona, R., Dargan, P.I., Daryani, A., Das Gupta, Rajat, Das Neves, J.,  
578 Dasa, T.T., Davitoiu, D.V., De La Hoz, F.P., De Leo, D., De Neve, J.W., De Steur, H.,  
579 Degefa, M.G., Degenhardt, L., Deiparine, S., Demoz, G.T., Denova-Gutiérrez, E.,  
580 Deribe, K., Dervenis, N., Des Jarlais, D.C., Dey, S., Dharmaratne, S.D., Dhimal, M.,  
581 Dinberu, M.T., Dirac, M.A., Djalalinia, S., Doan, L., Dokova, K., Doku, D.T., Dorsey,  
582 E.R., Doyle, K.E., Driscoll, T.R., Dubey, M., Dubljanin, E., Duken, E.E., Duncan, B.B.,  
583 Duraes, A.R., Ebrahimi, H., Ebrahimpour, S., Echko, M.M., Edessa, D., Edvardsson, D.,  
584 Effiong, A., Eggen, A.E., Ehrlich, J.R., El Bcheraoui, C., El-Khatib, Z., Elyazar, I.R.F.,  
585 Enayati, A., Endalifer, M.L., Endries, A.Y., Er, B., Erskine, H.E., Eskandarieh, S.,  
586 Esteghamati, A., Esteghamati, S., Fakhim, H., Faramarzi, M., Fareed, M., Farhadi, F.,  
587 Farid, T.A., Sá Farinha, C.S.E., Farioli, A., Faro, A., Farzadfar, F., Fazaeli, A.A., Feigin,  
588 V.L., Fentahun, N., Fereshtehnejad, S.M., Fernandes, E., Fernandes, J.C., Ferrari, A.J.,

589 Ferreira, M.L., Filip, I., Fischer, F., Fitzmaurice, C., Foigt, N.A., Foreman, K.J., Frank,  
590 T.D., Fukumoto, T., Fullman, N., Fürst, T., Furtado, J.M., Gakidou, E., Gall, S., Gallus,  
591 S., Ganji, M., Garcia-Basteiro, A.L., Gardner, W.M., Gebre, A.K., Gebremedhin, A.T.,  
592 Gebremichael, T.G., Gelano, T.F., Geleijnse, J.M., Genova-Maleras, R., Geramo,  
593 Y.C.D., Gething, P.W., Gezae, K.E., Ghadami, M.R., Ghadiri, K., Ghasemi-Kasman,  
594 M., Ghimire, M., Ghoshal, A.G., Gill, P.S., Gill, T.K., Ginawi, I.A., Giussani, G.,  
595 Gnedovskaya, E. V., Goldberg, E.M., Goli, S., Gómez-Dantés, H., Gona, P.N.,  
596 Gopalani, S.V., Gorman, T.M., Goulart, A.C., Goulart, B.N.G., Grada, A., Grosso, G.,  
597 Gugnani, H.C., Guillemin, F., Guo, Y., Gupta, P.C., Gupta, Rahul, Gupta, Rajeev,  
598 Gupta, T., Gutiérrez, R.A., Gyawali, B., Haagsma, J.A., Hachinski, V., Hafezi-Nejad,  
599 N., Bidgoli, H.H., Hagos, T.B., Hailegiyorgis, T.T., Haj-Mirzaian, Arvin, Haj-Mirzaian,  
600 Arya, Hamadeh, R.R., Hamidi, S., Handal, A.J., Hankey, G.J., Hao, Y., Harb, H.L.,  
601 Harikrishnan, S., Haririan, H., Haro, J.M., Hassankhani, H., Hassen, H.Y., Havmoeller,  
602 R., Hay, R.J., Hay, S.I., Hedayatizadeh-Omran, A., Heibati, B., Hendrie, D., Henok, A.,  
603 Heredia-Pi, I., Herteliu, C., Heydarpour, F., Heydarpour, P., Hibstu, D.T., Hoek, H.W.,  
604 Hoffman, H.J., Hole, M.K., Rad, E.H., Hoogar, P., Hosgood, H.D., Hosseini, S.M.,  
605 Hosseinzadeh, M., Hostiuc, M., Hostiuc, S., Hotez, P.J., Hoy, D.G., Hsairi, M., Htet,  
606 A.S., Huang, J.J., Iburg, K.M., Ikeda, C.T., Ilesanmi, O.S., Irvani, S.S.N., Irvine,  
607 C.M.S., Islam, S.M.S., Islami, F., Jacobsen, K.H., Jahangiry, L., Jahanmehr, N., Jain,  
608 S.K., Jakovljevic, M., James, S.L., Jayatilleke, A.U., Jeemon, P., Jha, R.P., Jha, V., Ji,  
609 J.S., Johnson, C.O., Jonas, J.B., Jonnagaddala, J., Shushtari, Z.J., Joshi, A., Jozwiak, J.J.,  
610 Jungari, S.B., Jürisson, M., Kabir, Z., Kadel, R., Kahsay, A., Kalani, R., Kanchan, T.,  
611 Kar, C., Karami, M., Karami Matin, B., Karch, A., Karema, C., Karimi, N., Karimi,  
612 S.M., Kasaeian, A., Kassa, D.H., Kassa, G.M., Kassa, T.D., Kassebaum, N.J.,  
613 Katikireddi, S.V., Kaul, A., Kawakami, N., Kazemi, Z., Kazemi Karyani, A.,

614 Keighobadi, M.M., Keiyoro, P.N., Kemmer, L., Kemp, G.R., Kengne, A.P., Keren, A.,  
615 Khader, Y.S., Khafaei, B., Khafaie, M.A., Khajavi, A., Khalid, N., Khalil, I.A., Khan,  
616 E.A., Khan, M.S., Khan, M.A., Khang, Y.H., Khater, M.M., Khazaei, M., Khoja, A.T.,  
617 Khosravi, A., Khosravi, M.H., Kiadaliri, A.A., Kidanemariam, Z.T., Kiirithio, D.N.,  
618 Kim, C. Il, Kim, D., Kim, Y.E., Kim, Y.J., Kimokoti, R.W., Kinfu, Y., Kisa, A.,  
619 Kissimova-Skarbek, K., Knudsen, A.K.S., Kocarnik, J.M., Kochhar, S., Kokubo, Y.,  
620 Kolola, T., Kopec, J.A., Kosen, S., Kotsakis, G.A., Koul, P.A., Koyanagi, A., Krishan,  
621 K., Krishnaswami, S., Krohn, K.J., Defo, B.K., Bicer, B.K., Kumar, G.A., Kumar, M.,  
622 Kuzin, I., Lad, D.P., Lad, S.D., Lafranconi, A., Laloo, R., Lallukka, T., Lami, F.H.,  
623 Lang, J.J., Langan, S.M., Lansingh, V.C., Latifi, A., Lau, K.M.M., Lazarus, J. V.,  
624 Leasher, J.L., Ledesma, J.R., Lee, P.H., Leigh, J., Leili, M., Leshargie, C.T., Leung, J.,  
625 Levi, M., Lewycka, S., Li, S., Li, Y., Liang, X., Liao, Y., Liben, M.L., Lim, L.L., Lim,  
626 S.S., Limenih, M.A., Linn, S., Liu, S., Looker, K.J., Lopez, A.D., Lorkowski, S., Lotufo,  
627 P.A., Lozano, R., Lucas, T.C.D., Lunevicius, R., Lyons, R.A., Ma, S., Macarayan,  
628 E.R.K., Mackay, M.T., Maddison, E.R., Madotto, F., Maghavani, D.P., Mai, H.T.,  
629 Majdan, M., Majdzadeh, R., Majeed, A., Malekzadeh, R., Malta, D.C., Mamun, A.A.,  
630 Manda, A.L., Manguerra, H., Mansournia, M.A., Mantilla Herrera, A.M., Mantovani,  
631 L.G., Maravilla, J.C., Marcenes, W., Marks, A., Martins-Melo, F.R., Martopullo, I.,  
632 März, W., Marzan, M.B., Massano, J., Massenburg, B.B., Mathur, M.R., Maulik, P.K.,  
633 Mazidi, M., McAlinden, C., McGrath, J.J., McKee, M., McMahon, B.J., Mehata, S.,  
634 Mehrotra, R., Mehta, K.M., Mehta, V., Mejia-Rodriguez, F., Mekonen, T., Melese, A.,  
635 Melku, M., Memiah, P.T.N., Memish, Z.A., Mendoza, W., Mengistu, G., Mensah, G.A.,  
636 Mereta, S.T., Meretoja, A., Meretoja, T.J., Mestrovic, T., Miazgowski, B., Miazgowski,  
637 T., Millea, A.I., Miller, T.R., Mini, G.K., Mirarefin, M., Mirica, A., Mirrakhimov,  
638 E.M., Misganaw, A.T., Mitchell, P.B., Mitiku, H., Moazen, B., Mohajer, B.,

639 Mohammad, K.A., Mohammadi, M., Mohammadifard, N., Mohammadnia-Afrouzi, M.,  
640 Mohammed, M.A., Mohammed, S., Mohebi, F., Mokdad, A.H., Molokhia, M., Monasta,  
641 L., Montanez, J.C., Moosazadeh, M., Moradi, G., Moradi, M., Moradi-Lakeh, M.,  
642 Moradinazar, M., Moraga, P., Morawska, L., Velásquez, I.M., Morgado-Da-Costa, J.,  
643 Morrison, S.D., Moschos, M.M., Mousavi, S.M., Mruts, K.B., Muche, A.A., Muchie,  
644 K.F., Mueller, U.O., Muhammed, O.S., Mukhopadhyay, S., Muller, K., Mumford, J.E.,  
645 Murthy, G.V.S., Musa, K.I., Mustafa, G., Nabhan, A.F., Nagata, C., Nagel, G., Naghavi,  
646 M., Naheed, A., Nahvijou, A., Naik, G., Najafi, F., Nam, H.S., Nangia, V., Nansseu,  
647 J.R., Neamati, N., Negoi, I., Negoi, R.I., Neupane, S., Newton, C.R.J., Ngunjiri, J.W.,  
648 Nguyen, A.Q., Nguyen, G., Nguyen, Ha Thu, Nguyen, H.L.T., Nguyen, Huong Thanh,  
649 Nguyen, L.H., Nguyen, M., Nguyen, N.B., Nguyen, S.H., Nichols, E., Ningrum, D.N.A.,  
650 Nixon, M.R., Nomura, S., Noroozi, M., Norrving, B., Noubiap, J.J., Nouri, H.R.,  
651 Shiadeh, M.N., Nowroozi, M.R., Nsoesie, E.O., Nyasulu, P.S., Odell, C.M., Ofori-  
652 Asenso, R., Ogbo, F.A., Oh, I.H., Oladimeji, O., Olagunju, A.T., Olagunju, T.O.,  
653 Olivares, P.R., Olsen, H.E., Olusanya, B.O., Olusanya, J.O., Ong, K.L., Ong, S.K.,  
654 Oren, E., Ortiz, A., Ota, E., Otstavnov, S.S., Overland, S., Owolabi, M.O., Mahesh,  
655 P.A., Pacella, R., Pakhare, A.P., Pakpour, A.H., Pana, A., Panda-Jonas, S., Park, E.K.,  
656 Park, J., Parry, C.D.H., Parsian, H., Pasdar, Y., Patel, S., Patil, S.T., Patle, A., Patton,  
657 G.C., Paturi, V.R., Paudel, D., Paulson, K.R., Pearce, N., Pereira, A., Pereira, D.M.,  
658 Perico, N., Pesudovs, K., Petzold, M., Pham, H.Q., Phillips, M.R., Pigott, D.M., Pillay,  
659 J.D., Piradov, M.A., Pirsaeheb, M., Pishgar, F., Plana-Ripoll, O., Polinder, S., Popova, S.,  
660 Postma, M.J., Pourshams, A., Poustchi, H., Prabhakaran, D., Prakash, S., Prakash, V.,  
661 Prasad, N., Purcell, C.A., Qorbani, M., Quistberg, D.A., Radfar, A., Rafay, A., Rafiei,  
662 A., Rahim, F., Rahimi, K., Rahimi, Z., Rahimi-Movaghar, A., Rahimi-Movaghar, V.,  
663 Rahman, M., Ur Rahman, M.H., Rahman, M.A., Rahman, S.U., Rai, R.K., Rajati, F.,

664 Ranjan, P., Rao, P.C., Rasella, D., Rawaf, D.L., Rawaf, S., Reddy, K.S., Reiner, R.C.,  
665 Reitsma, M.B., Remuzzi, G., Renzaho, A.M.N., Resnikoff, S., Rezaei, S., Rezai, M.S.,  
666 Ribeiro, A.L.P., Roberts, N.L.S., Robinson, S.R., Roeber, L., Ronfani, L., Roshandel,  
667 G., Rostami, A., Roth, G.A., Rothenbacher, D., Rubagotti, E., Sachdev, P.S., Sadat, N.,  
668 Sadeghi, E., Saeedi Moghaddam, S., Safari, H., Safari, Y., Safari-Faramani, R.,  
669 Safdarian, M., Safi, S., Safiri, S., Sagar, R., Sahebkar, A., Sahraian, M.A., Sajadi, H.S.,  
670 Salam, N., Salama, J.S., Salamati, P., Saleem, Z., Salimi, Y., Salimzadeh, H., Salomon,  
671 J.A., Salvi, S.S., Salz, I., Samy, A.M., Sanabria, J., Sanchez-Nino, M.D., Santomauro,  
672 D.F., Santos, I.S., Santos, J.V., Santric Milicevic, M.M., Sao Jose, B.P., Sardana, M.,  
673 Sarker, A.R., Sarmiento-Suárez, R., Sarrafzadegan, N., Sartorius, B., Sarvi, S., Sathian,  
674 B., Satpathy, M., Sawant, A.R., Sawhney, M., Saxena, S., Schaeffner, E., Schmidt, M.I.,  
675 Schneider, I.J.C., Schutte, A.E., Schwebel, D.C., Schwendicke, F., Scott, J.G., Sekerija,  
676 M., Sepanlou, S.G., Serván-Mori, E., Seyedmousavi, S., Shabaninejad, H., Shafieesabet,  
677 A., Shahbazi, M., Shaheen, A.A., Shaikh, M.A., Shams-Beyranvand, M., Shamsi, M.,  
678 Sharafi, H., Sharafi, K., Sharif, M., Sharif-Alhoseini, M., Sharma, J., Sharma, R., She,  
679 J., Sheikh, A., Shi, P., Shibuya, K., Shiferaw, M.S., Shigematsu, M., Shiri, R.,  
680 Shirkoohi, R., Shiue, I., Shokoohinia, Y., Shokraneh, F., Shoman, H., Shrime, M.G., Si,  
681 S., Siabani, S., Sibai, A.M., Siddiqi, T.J., Sigfusdottir, I.D., Sigurvinsdottir, R., Silva,  
682 D.A.S., Silva, J.P., Silveira, D.G.A., Singam, N.S.V., Singh, J.A., Singh, N.P., Singh,  
683 V., Sinha, D.N., Skiadaresi, E., Skirbekk, V., Sliwa, K., Smith, D.L., Smith, M., Filho,  
684 A.M.S., Sobaih, B.H., Sobhani, S., Soofi, M., Sorensen, R.J.D., Soyiri, I.N., Sposato,  
685 L.A., Sreeramareddy, C.T., Srinivasan, V., Stanaway, J.D., Starodubov, V.I., Stein, D.J.,  
686 Steiner, C., Steiner, T.J., Stokes, M.A., Stovner, L.J., Subart, M.L., Sudaryanto, A.,  
687 Sufiyan, M.B., Sulo, G., Sunguya, B.F., Sur, P.J., Sykes, B.L., Sylaja, P.N., Sylte, D.O.,  
688 Szoeki, C.E.I., Tabarés-Seisdedos, R., Tabuchi, T., Tadakamadla, S.K., Tandon, N.,

689 Tassew, S.G., Tavakkoli, M., Taveira, N., Taylor, H.R., Tehrani-Banihashemi, A.,  
690 Tekalign, T.G., Tekelemedhin, S.W., Tekle, M.G., Temsah, M.H., Temsah, O., Terkawi,  
691 A.S., Tessema, B., Teweldemedhin, M., Thankappan, K.R., Theis, A.,  
692 Thirunavukkarasu, S., Thomas, N., Tilahun, B., To, Q.G., Tonelli, M., Topor-Madry, R.,  
693 Torre, A.E., Tortajada-Girbés, M., Touvier, M., Tovani-Palone, M.R., Towbin, J.A.,  
694 Tran, B.X., Tran, K.B., Troeger, C.E., Tsadik, A.G., Tsoi, D., Tudor Car, L., Tyrovolas,  
695 S., Ukwaja, K.N., Ullah, I., Undurraga, E.A., Updike, R.L., Usman, M.S., Uthman,  
696 O.A., Vaduganathan, M., Vaezi, A., Valdez, P.R., Varavikova, E., Varughese, S.,  
697 Vasankari, T.J., Venketasubramanian, N., Villafaina, S., Violante, F.S., Vladimirov,  
698 S.K., Vlassov, V., Vollset, S.E., Vos, T., Vosoughi, K., Vujcic, I.S., Wagnew, F.S.,  
699 Waheed, Y., Wang, Y., Wang, Y.P., Weiderpass, E., Weintraub, R.G., Weiss, D.J.,  
700 Weldegebreal, F., Weldegewergs, K.G., Werdecker, A., West, T.E., Westerman, R.,  
701 Whiteford, H.A., Widecka, J., Wijeratne, T., Williams, H.C., Wilner, L.B., Wilson, S.,  
702 Winkler, A.S., Wiyeh, A.B., Wiysonge, C.S., Wolfe, C.D.A., Woolf, A.D., Wyper,  
703 G.M.A., Xavier, D., Xu, G., Yadgir, S., Yahyazadeh Jabbari, S.H., Yamada, T., Yan,  
704 L.L., Yano, Y., Yaseri, M., Yasin, Y.J., Yeshaneh, A., Yimer, E.M., Yip, P., Yisma, E.,  
705 Yonemoto, N., Yoon, S.J., Yotebieng, M., Younis, M.Z., Yousefifard, M., Yu, C.,  
706 Zadnik, V., Zaidi, Z., Zaman, S. Bin, Zamani, M., Zandian, H., Zar, H.J., Zenebe, Z.M.,  
707 Zipkin, B., Zhou, M., Zodpey, S., Zucker, I., Zuhlke, L.J., Murray, C.J.L., 2018. Global,  
708 regional, and national disability-adjusted life-years (DALYs) for 359 diseases and  
709 injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-  
710 2017: A systematic analysis for the Global Burden of Disease Study 2017. *Lancet*.  
711 [https://doi.org/10.1016/S0140-6736\(18\)32335-3](https://doi.org/10.1016/S0140-6736(18)32335-3)

712 Levis, B., Benedetti, A., Thombs, B.D., 2019. Accuracy of Patient Health Questionnaire-9  
713 (PHQ-9) for screening to detect major depression: individual participant data meta-

714 analysis. *BMJ* 11476. <https://doi.org/10.1136/bmj.11476>

715 Lewis, G., Pelosi, A.J., Araya, R., Dunn, G., 1992. Measuring psychiatric disorder in the  
716 community: A standardized assessment for use by lay interviewers. *Psychol. Med.*  
717 <https://doi.org/10.1017/S0033291700030415>

718 Luppá, M., Sikorski, C., Luck, T., Ehreke, L., Konnopka, A., Wiese, B., Weyerer, S., König,  
719 H.H., Riedel-Heller, S.G., 2012. Age- and gender-specific prevalence of depression in  
720 latest-life - Systematic review and meta-analysis. *J. Affect. Disord.*  
721 <https://doi.org/10.1016/j.jad.2010.11.033>

722 Maske, U.E., Buttery, A.K., Beesdo-Baum, K., Riedel-Heller, S., Hapke, U., Busch, M.A.,  
723 2016. Prevalence and correlates of DSM-IV-TR major depressive disorder, self-reported  
724 diagnosed depression and current depressive symptoms among adults in Germany. *J.*  
725 *Affect. Disord.* 190, 167–177. <https://doi.org/10.1016/j.jad.2015.10.006>

726 Moriarty, A.S., Gilbody, S., McMillan, D., Manea, L., 2015. Screening and case finding for  
727 major depressive disorder using the Patient Health Questionnaire (PHQ-9): a meta-  
728 analysis. *Gen. Hosp. Psychiatry* 37, 567–576.  
729 <https://doi.org/10.1016/j.genhosppsy.2015.06.012>

730 Moussavi, S., Chatterji, S., Verdes, E., Tandon, A., Patel, V., Ustun, B., 2007. Depression,  
731 chronic diseases, and decrements in health: results from the World Health Surveys.  
732 *Lancet* 370, 851–858. [https://doi.org/10.1016/S0140-6736\(07\)61415-9](https://doi.org/10.1016/S0140-6736(07)61415-9)

733 NHS Digital, 2014. Adult Psychiatric Morbidity Survey: Survey of Mental Health and  
734 Wellbeing, England, 2014 - NHS Digital [WWW Document]. APMS.

735 Niedzwiedz, C.L., Katikireddi, S.V., Reeves, A., McKee, M., Stuckler, D., 2017. Economic  
736 insecurity during the Great Recession and metabolic, inflammatory and liver function

737 biomarkers: analysis of the UK Household Longitudinal Study. *J. Epidemiol.*  
738 *Community Health* 71, 1005–1013. <https://doi.org/10.1136/jech-2017-209105>

739 Onyike, C.U., Crum, R.M., Lee, H.B., Lyketsos, C.G., Eaton, W.W., 2003. Is Obesity  
740 Associated with Major Depression? Results from the Third National Health and  
741 Nutrition Examination Survey. *Am. J. Epidemiol.* <https://doi.org/10.1093/aje/kwg275>

742 Patel, V., Burns, J.K., Dhingra, M., Tarver, L., Kohrt, B.A., Lund, C., 2018a. Income  
743 inequality and depression: a systematic review and meta-analysis of the association and  
744 a scoping review of mechanisms. *World Psychiatry* 17, 76–89.  
745 <https://doi.org/10.1002/wps.20492>

746 Patel, V., Burns, J.K., Dhingra, M., Tarver, L., Kohrt, B.A., Lund, C., 2018b. Income  
747 inequality and depression: a systematic review and meta-analysis of the association and  
748 a scoping review of mechanisms. *World Psychiatry* 17, 76–89.  
749 <https://doi.org/10.1002/wps.20492>

750 Patton, G.C., Coffey, C., Romaniuk, H., Mackinnon, A., Carlin, J.B., Degenhardt, L., Olsson,  
751 C.A., Moran, P., 2014. The prognosis of common mental disorders in adolescents: a 14-  
752 year prospective cohort study. *Lancet* 383, 1404–1411. <https://doi.org/10.1016/S0140->  
753 [6736\(13\)62116-9](https://doi.org/10.1016/S0140-6736(13)62116-9)

754 Perry, B.I., Khandaker, G.M., Marwaha, S., Thompson, A., Zammit, S., Singh, S.P.,  
755 Upthegrove, R., 2020. Insulin resistance and obesity, and their association with  
756 depression in relatively young people: findings from a large UK birth cohort. *Psychol.*  
757 *Med.* 50, 556–565. <https://doi.org/10.1017/S0033291719000308>

758 Pinto-Meza, A., Serrano-Blanco, A., Peñarrubia, M.T., Blanco, E., Haro, J.M., 2005.  
759 Assessing depression in primary care with the PHQ-9: Can it be carried out over the  
760 telephone? *J. Gen. Intern. Med.* <https://doi.org/10.1111/j.1525-1497.2005.0144.x>



761 Rai, D., Zitko, P., Jones, K., Lynch, J., Araya, R., 2013. Country- and individual-level  
762 socioeconomic determinants of depression: Multilevel cross-national comparison. *Br. J.*  
763 *Psychiatry*. <https://doi.org/10.1192/bjp.bp.112.112482>

764 Reibling, N., 2010. Healthcare systems in Europe: towards an incorporation of patient access.  
765 *J. Eur. Soc. Policy* 20, 5–18. <https://doi.org/10.1177/0958928709352406>

766 Rohde, P., Lewinsohn, P.M., Seeley, J.R., 1997. Comparability of telephone and face-to-face  
767 interviews in assessing axis I and II disorders. *Am. J. Psychiatry*.  
768 <https://doi.org/10.1176/ajp.154.11.1593>

769 Salk, R.H., Hyde, J.S., Abramson, L.Y., 2017. Gender differences in depression in  
770 representative national samples: Meta-analyses of diagnoses and symptoms. *Psychol.*  
771 *Bull.* <https://doi.org/10.1037/bul0000102>

772 Sivertsen, H., Bjørkløf, G.H., Engedal, K., Selbæk, G., Helvik, A.S., 2015. Depression and  
773 quality of life in older persons: A review. *Dement. Geriatr. Cogn. Disord.*  
774 <https://doi.org/10.1159/000437299>

775 Stata Statistical Software: Release 16 [WWW Document], 2019. . StataCorp LLC.

776 Szklo, M., Nieto, J., 2014. *Epidemiology, Beyond the Basics (3rd Edition)*, Sudbury, MA:  
777 Jones & Bartlett Publishers.

778 West, B.T., McCabe, S.E., 2012. Incorporating complex sample design effects when only  
779 final survey weights are available. *Stata J.*  
780 <https://doi.org/10.1177/1536867X1201200410>

781 World Health Organisation (WHO), 2011. Global burden of mental disorders and the need  
782 for a comprehensive , coordinated response from health and social sectors at the country  
783 level Report by the Secretariat, World Health Organization.

784 World Health Organization, 2017. Depression and other common mental disorders: global  
785 health estimates. *World Heal. Organ.* 1–24. <https://doi.org/CC BY-NC-SA 3.0 IGO>

786 Wu, Y., Levis, B., Riehm, K.E., Saadat, N., Levis, A.W., Azar, M., Rice, D.B., Boruff, J.,  
787 Cuijpers, P., Gilbody, S., Ioannidis, J.P.A., Kloda, L.A., McMillan, D., Patten, S.B.,  
788 Shrier, I., Ziegelstein, R.C., Akena, D.H., Arroll, B., Ayalon, L., Baradaran, H.R.,  
789 Baron, M., Bombardier, C.H., Butterworth, P., Carter, G., Chagas, M.H., Chan, J.C.N.,  
790 Cholera, R., Conwell, Y., de Man-van Ginkel, J.M., Fann, J.R., Fischer, F.H., Fung, D.,  
791 Gelaye, B., Goodyear-Smith, F., Greeno, C.G., Hall, B.J., Harrison, P.A., Härter, M.,  
792 Hegerl, U., Hides, L., Hobfoll, S.E., Hudson, M., Hyphantis, T., Inagaki, M., Jetté, N.,  
793 Khamseh, M.E., Kiely, K.M., Kwan, Y., Lamers, F., Liu, S.-I., Lotrakul, M., Loureiro,  
794 S.R., Löwe, B., McGuire, A., Mohd-Sidik, S., Munhoz, T.N., Muramatsu, K., Osório,  
795 F.L., Patel, V., Pence, B.W., Persoons, P., Picardi, A., Reuter, K., Rooney, A.G., Santos,  
796 I.S., Shaaban, J., Sidebottom, A., Simning, A., Stafford, L., Sung, S., Tan, P.L.L.,  
797 Turner, A., van Weert, H.C., White, J., Whooley, M.A., Winkley, K., Yamada, M.,  
798 Benedetti, A., Thombs, B.D., 2019. Equivalency of the diagnostic accuracy of the PHQ-  
799 8 and PHQ-9: a systematic review and individual participant data meta-analysis.  
800 *Psychol. Med.* 1–13. <https://doi.org/10.1017/S0033291719001314>

801

**Table 1. Distribution of the study covariates. European Health Interview Survey 2014/2015.**

	<b>Total</b>		<b>Men</b>		<b>Women</b>	
	<b>(n=17,652)</b>		<b>(n=7,515; 46.3% 95%CI: 45.3-47.3)</b>		<b>(n=9,637; 53.8% 95%CI: 52.8-54.7)</b>	
	<b>n</b>	<b>% (95%CI)</b>	<b>n</b>	<b>% (95%CI)</b>	<b>n</b>	<b>% (95%CI)</b>
<b>Age</b>						
16 to 29	1,205	18.2 (17.2-19.2)	489	17.8 (16.3-19.4)	716	18.5 (17.2-19.9)
30 to 44	3,140	25.3 (24.5-26.3)	1,282	25.7 (24.4-27.1)	1,858	25.1 (24.0-26.3)
45 to 59	4,560	26.3 (25.5-27.1)	1,956	26.8 (25.6-28.0)	2,604	25.9 (24.8-26.9)
60 to 74	5,774	20.2 (19.6-20.8)	2,663	20.7 (19.8-21.7)	3,111	19.7 (18.9-20.5)
75 or more	2,473	10.0-9.5-10.5)	1,225	9.0 (8.4-9.6)	1,348	10.9 (10.2-11.5)
<b>Interview method</b>						
Face-to-face	4,322	26.3 (25.4-27.2)	1,873	25.7 (24.4-27.0)	2,449	26.8 (25.7-28.0)
Telephone	12,830	73.7 (72.8-74.6)	5,642	74.3 (73.0-75.7)	7,118	73.2 (72.0-74.3)
<b>Birthplace</b>						
Native-born	15,674	88.1 (87.4-88.8)	6,866	88.1 (87.1-89.0)	8,808	88.2 (87.2-89.1)
EU Member State	529	4.2 (3.8-4.7)	221	4.3 (3.6-5.0)	308	4.1 (3.6-4.7)
Non-EU country	949	7.7 (7.1-8.3)	428	7.6 (6.8-8.6)	521	7.7 (7.0-8.6)
<b>Residence area</b>						
Densely-populated	10,061	54.4 (53.4-55.4)	4,382	53.4 (51.9-55.0)	5,677	55.2 (53.9-56.5)
Intermediate-populated	4,651	29.1 (28.2-30.0)	2,048	29.9 (28.5-31.3)	2,603	28.4 (27.3-29.6)
Thinly-populated	2,440	16.5 (15.8-17.3)	1,083	16.7 (15.5-17.9)	1,357	16.3 (15.4-17.4)
<b>Body Mass Index</b>						
Less than 18.5	296	2.2 (1.9-2.6)	81	1.5 (1.1-2.0)	215	2.8 (2.3-3.3)
18.5 to less than 25	7,184	45.1 (44.0-46.1)	2,822	40.9 (39.4-42.4)	4,362	48.7 (47.4-50.0)
25 to less than 30	6,197	33.7 (32.8-34.7)	3,120	38.7 (37.2-40.1)	3,077	29.5 (28.4-30.7)
30 or more	3,475	19.0 (18.3-19.8)	1,492	19.0 (17.9-20.1)	1,983	19.1 (18.1-20.1)
<b>Social Support</b>						
Strong	8,989	50.9 (49.9-51.9)	3,698	47.6 (46.1-49.1)	5,291	53.7 (52.4-55.0)
Moderate	6,612	40.0 (39.0-40.9)	3,046	42.4 (40.9-43.9)	3,566	37.9 (36.7-39.2)
Poor	1,551	9.2 (8.6-9.8)	771	10.1 (9.0-11.1)	780	8.4 (7.7-9.2)

n: absolute frequency of individuals (without weighting); %: Percentage for total sample and prevalence for Depression and severity levels. 95%CI: 95% Confidence Interval. All percentages and standard errors were calculated taking into account the weights derived from the complex sample design using the Taylor series linearization method.


**Table 2. Prevalence of depressive symptoms and of probable depressive disorder. European Health Interview Survey 2014/2015. Bivariable analysis.**

	Depressive symptoms			Probable depressive disorder
	Mild (PHQ-8: 5-9) % (95%CI)	Moderate (PHQ-8: 10-14) % (95%CI)	Severe (PHQ-8≥15) % (95%CI)	(PHQ-8≥10) % (95%CI)
<b>Total (n=17,152)</b>	11.3 (10.6-11.9)	4.2 (3.8-4.6)	3.3 (3.0-3.7)	7.5 (7.0-8.0)
<b>Age</b>				
16 to 29 (n=1,205)	11.3 (9.4-13.6)	3.7 (2.6-5.2)	2.4 (1.6-3.6)	6.2 (4.7-7.9)
30 to 44 (n=3,140)	10.8 (9.6-12.1)	3.7 (3.0-4.6)	2.9 (2.3-3.6)	6.6 (5.7-7.7)
45 to 59 (n=4,560)	12.0 (11.0-13.2)	5.1 (4.5-5.9)	5.3 (4.6-6.1)	10.4 (9.5-11.5)
60 to 74 (n=5,774)	10.3 (9.4-11.3)	3.8 (3.3-4.4)	2.5 (2.1-3.0)	6.3 (5.3-7.1)
75 or more (n=2,473)	12.2 (10.8-13.7)	4.2 (3.4-5.2)	2.4 (1.7-3.2)	6.6 (5.5-7.8)
<b>Men (n=7,515)</b>	9.3 (8.5-10.2)	3.5 (3.0-4.1)	2.7 (2.3-3.2)	6.2 (5.6-6.9)
<b>Age</b>				
16 to 29 (n=489)	7.7 (5.4-10.8)	2.6 (1.4-5.0)	1.2 (0.6-2.4)	3.8 (2.3-6.2)
30 to 44 (n=1,282)	8.9 (7.2-10.8)	2.8 (1.9-4.1)	2.9 (2.1-4.1)	5.7 (4.4-7.4)
45 to 59 (n=1,956)	11.5 (9.9-13.3)	4.8 (3.8-6.0)	4.5 (3.6-5.7)	9.3 (7.9-10.9)
60 to 74 (n=2,663)	8.1 (7.0-9.4)	3.7 (2.9-4.6)	2.0 (1.5-2.7)	5.7 (4.7-6.8)
75 or more (n=1,125)	10.2 (8.3-12.05)	2.9 (2.0-4.2)	1.4 (0.8-2.7)	4.3 (3.1-5.9)
<b>Women (n=9,637)</b>	12.9 (12.0-13.8)	4.8 (4.2-5.3)	3.8 (3.3-4.4)	8.6 (7.9-9.3)
<b>Age</b>				
16 to 29 (n=716)	14.4 (11.6-17.8)	4.6 (3.1-6.9)	3.4 (2.1-5.5)	8.1 (5.9-10.8)
30 to 44 (n=1,858)	12.5 (10.8-14.3)	4.5 (3.5-5.8)	2.9 (2.1-3.9)	7.4 (6.1-8.9)
45 to 59 (n=2,604)	12.5 (11.1-14.0)	5.5 (4.6-6.6)	6.0 (5.0-7.1)	11.5 (10.1-12.9)
60 to 74 (n=3,111)	12.3 (11.0-13.8)	4.0 (3.3-4.8)	3.0 (2.4-3.7)	6.9 (6.0-8.0)
75 or more (n=1,348)	13.5 (11.6-15.8)	5.1 (3.9-6.7)	3.0 (2.1-4.3)	8.6 (7.9-9.3)

n: absolute frequency of individuals (without weighting); %: Prevalence of depressive symptoms and probable depressive disorder. 95%CI: 95% Confidence Interval.

All percentages and standard errors were calculated taking into account the weights derived from the complex sample design using the Taylor series linearization method.

Figure 1. Prevalence (%) of probable depressive disorder (PHQ-8 $\geq$ 10) by age and sex.



**Table 3. Relationship of depressive symptoms with age and sex. European Health Interview Survey 2014/2015. Bivariable and multivariable analysis.**

	Mild symptoms (PHQ-8: 5-9; 11.3% 95%CI: 10.6-11.9)		Moderate symptoms (PHQ-8: 10-14; 4.2% 95%CI: 3.8-4.6)		Severe symptoms (PHQ-8≥15; 3.3% 95%CI: 3.0-3.7)		<i>p</i> (RPR)	<i>p</i> (aROR)
	ROR (95%CI)	aROR (95%CI)	ROR (95%CI)	aROR (95%CI)	ROR (95%CI)	aROR (95%CI)		
<b>Total (n=17,152)</b>								
<b>Age</b>							<0.001	<0.001
16 to 29	1.00	1.00	1.00	1.00	1.00	1.00		
30 to 44	0.95 (0.74-1.22)	0.94 (0.73-1.21)	1.00 (0.66-1.52)	1.02 (0.67-1.59)	1.19 (0.73-1.92)	1.35 (0.82-2.22)		
45 to 59	1.12 (0.89-1.43)	1.06 (0.83-1.35)	1.47 (0.99-2.16)	1.41 (0.93-2.14)	2.32 (1.48-3.63)	2.55 (1.60-4.06)		
60 to 74	0.90 (0.71-1.12)	0.87 (0.68-1.11)	1.01 (0.69-1.50)	1.02 (0.67-1.56)	1.02 (0.65-1.62)	1.21 (0.75-1.95)		
75 or more	1.09-0.85-1.40)	1.01 (0.78-1.31)	1.14 (0.75-1.75)	1.10 (0.71-1.68)	0.99 (0.58-1.68)	0.91 (0.53-1.58)		
<b>Men (n=7,515)</b>								
<b>Age</b>							<0.001	<0.001
16 to 29	1.00	1.00	1.00	1.00	1.00	1.00		
30 to 44	1.19 (0.77-1.86)	1.28 (0.82-2.00)	1.12 (0.51-2.43)	1.18 (0.52-2.67)	2.46 (1.14-5.35)	3.07 (1.37-6.83)		
45 to 59	1.68 (1.11-2.53)	1.76 (1.15-2.71)	2.03 (0.99-4.14)	2.07 (0.94-4.55)	4.13 (1.99-8.59)	5.38 (2.51-11.53)		
60 to 74	1.08 (0.72-1.63)	1.16 (0.76-1.79)	1.43 (0.71-2.92)	1.50 (0.68-3.29)	1.69 (0.80-3.59)	2.31 (1.06-5.01)		
75 or more	1.38 (0.89-2.15)	1.32 (0.83-2.10)	1.12 (0.52-2.46)	1.11 (0.51-2.43)	1.20 (0.47-3.09)	1.27 (0.48-3.38)		
<b>Women (n=9, 637)</b>								
<b>Age</b>							<0.001	<0.001
16 to 29	1.00	1.00	1.00	1.00	1.00	1.00		
30 to 44	0.84 (0.62-1.13)	0.79 (0.59-1.08)	0.94 (0.5-1.54)	0.95 (0.57-1.57)	0.81 (0.44-1.47)	0.86 (0.46-1.60)		
45 to 59	0.89 (0.66-1.18)	0.77 (0.57-1.04)	1.21 (0.76-1.91)	1.10 (0.67-1.79)	1.78 (1.04-3.06)	1.75 (0.99-3.10)		
60 to 74	0.82 (0.61-1.09)	0.73 (0.54-1.00)	0.82 (0.51-1.31)	0.80 (0.48-1.31)	0.83 (0.48-1.46)	0.88 (0.49-1.58)		
75 or more	0.93 (0.69-1.27)	0.89 (0.65-1.22)	1.10 (0.66-1.82)	1.07 (0.65-1.76)	0.88 (0.47-1.65)	0.76 (0.39-1.45)		

n: absolute frequency of individuals (without weighting); %: prevalence of severity of depressive symptoms; 95%CI: 95% Confidence Interval; ROR: Relative Odds Ratio; aROR: Relative Odds Ratio adjusted for interview method, birthplace, degree of urbanization of the individuals' residence area, Body Mass Index and social support (OSS). In the total sample aROR multivariable models were also adjusted by sex; *p* (RPR): and *p* (aROR): *p* value for age from Wald tests for bivariable and multivariable models respectively.

All analyses were performed taking into account the weights derived from the complex sample design using the Taylor series linearization method.

**Table 4. Relationship of probable depressive disorder with age and sex. European Health Interview Survey 2014/2015. Bivariable and multivariable analysis.**

	Probable depressive disorder (PHQ-8 $\geq$ 10: 7.5%; 95% CI: 7.0-8.0)			
	OR (95%CI)	<i>p</i>	aOR (95%CI)	<i>p</i>
<b>Total sample (n=17,152)</b>				
<b>Age</b>		<0.001		<0.001
16 to 29	1.00		1.00	
30 to 44	1.08 (0.78-1.49)		1.17 (0.84-1.63)	
45 to 59	1.78 (1.32-2.49)		1.82 (1.32-2.50)	
60 to 74	1.03 (0.76-1.39)		1.12 (0.81-1.55)	
75 or more	1.07 (0.77-1.50)		1.02 (0.73-1.44)	
<b>Men (n=7,515)</b>				
<b>Age</b>		<0.001		<0.001
16 to 29	1.00		1.00	
30 to 44	1.52 (0.55-2.71)		1.70 (0.93-3.12)	
45 to 59	2.56 (1.49-4.40)		2.84 (1.57-5.14)	
60 to 74	1.51 (0.87-2.59)		1.74 (0.96-3.16)	
75 or more	1.12 (0.61-2.07)		1.12 (0.60-2.12)	
<b>Women (n=9,637)</b>				
<b>Age</b>		<0.001		<0.001
16 to 29	1.00		1.00	
30 to 44	0.91 (0.62-1.34)		0.95 (0.63-1.42)	
45 to 59	1.48 (1.03-2.12)		1.43 (0.97-2.09)	
60 to 74	0.55 (0.59-1.22)		0.88 (0.59-1.30)	
75 or more	1.02 (0.68-1.51)		0.95 (0.63-1.42)	

n: absolute frequency of individuals (without weighting); %: prevalence of probable depressive disorder; 95%CI: 95% Confidence Interval; *p*: *p* value for age from Wald tests for models; OR: Odds Ratio; aOR: Odds Ratio adjusted for interview method, birthplace, degree of urbanization of the individuals' residence area, Body Mass Index and social support (OSS). In the total sample aOR multivariable models were also adjusted by sex.

All analyses were performed taking into account the weights derived from the complex sample design using the Taylor series linearization method.